

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure–Activity Relationships


Leo Leung,^{†,§} Dan Niculescu-Duvaz,^{†,§} Deborah Smithen,^{†,§} Filipa Lopes,^{†,§} Cedric Callens,[§] Robert McLeary,^{†,§} Grazia Saturno,[‡] Lawrence Davies,[§] Mohammed Aljarah,^{†,§} Michael Brown,^{†,§} Louise Johnson,[§] Alfonso Zambon,[§] Tim Chambers,[‡] Delphine Ménard,[§] Natasha Bayliss,[§] Ruth Knight,[§] Laura Fish,[§] Rae Lawrence,[†] Mairi Challinor,[†] HaoRan Tang,[‡] Richard Marais,[‡] and Caroline Springer^{*,†,§}

[†]Drug Discovery Unit, Cancer Research UK Manchester Institute and [‡]Molecular Oncology Team, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield SK10 4TG, United Kingdom

[§]Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, United Kingdom

Supporting Information

ABSTRACT: Lysyl oxidase (LOX) is a secreted copper-dependent amine oxidase that cross-links collagens and elastin in the extracellular matrix and is a critical mediator of tumor growth and metastatic spread. LOX is a target for cancer therapy, and thus the search for therapeutic agents against LOX has been widely sought. We report herein the medicinal chemistry discovery of a series of LOX inhibitors bearing an aminomethylenethiophene (AMT) scaffold. High-throughput screening provided the initial hits. Structure–activity relationship (SAR) studies led to the discovery of AMT inhibitors with sub-micromolar half-maximal inhibitory concentrations (IC₅₀) in a LOX enzyme activity assay. Further SAR optimization yielded the orally bioavailable LOX inhibitor **CCT365623** with good anti-LOX potency, selectivity, pharmacokinetic properties, as well as anti-metastatic efficacy.



INTRODUCTION

Lysyl oxidase (LOX) and its family members LOX-like (LOXL) 1–4 are copper-dependent amine oxidases that covalently cross-link collagens and elastin in the tumor extracellular matrix.^{1–4} LOX is secreted as a catalytically inactive 50 kDa pro-protein, which is cleaved to an active 32 kDa enzyme by proteases such as procollagen C-proteinase. LOX and LOXL1–4 have variable N-termini, and they share a highly conserved C-terminus, where the catalytic domain is located. The catalytic site comprises a copper binding motif and a covalently bound lysine tyrosylquinone (LTQ) cofactor, where peptidyl lysine residues (H₂NCH₂R) are converted to the corresponding α -amino adipic- δ -semialdehyde (O=CHR) in an oxidative deamination reaction.³ The newly formed aldehyde residues undergo spontaneous cross-linking with adjacent nucleophilic functionalities, leading to the insoluble extracellular protein matrices.

LOX and LOXL2 also have important roles in promoting tumor growth in many types of cancer.^{5–12} In particular, LOX has been demonstrated to be a critical mediator of cancer metastasis.¹³ Therapeutic agents targeting the activity of LOX are thus proposed as cancer treatments, especially against metastasis where no effective therapeutic methods are currently available.

Until recently, no druglike small molecule inhibitors of LOX itself have been reported. Noticeably, the irreversible inhibitor

β -aminopropionitrile^{14,15} (BAPN) has found widespread applications in LOX-family-related biological studies (Figure 1), although the lack of amenable sites for chemical




Figure 1. Small molecule inhibitors of LOX-family enzymes.

modification has prevented its development into a clinically optimal drug. More recently, haloallylamine-based inhibitors PXS-S1A and PXS-S2A (full structures not disclosed)¹⁶ and trifluoromethyl (CF₃)-substituted aminomethylene-pyridine **1** were reported to be potent selective inhibitors of one of the family members, LOXL2; the latter also showed weak inhibition against LOX.^{17,18} Intriguingly, analogues of pyridine **1** without the CF₃ functionality were less selective toward LOXL2, with low micromolar IC₅₀s against LOX.

We have recently reported the elucidation of a mechanism by which LOX drives tumor progression in breast cancer¹⁹ and

Received: February 21, 2019

Published: May 9, 2019


that treatment with the aminomethylenethiophene (AMT) inhibitor CCT365623 (**9f**) led to significant reduction in tumor growth and, importantly, in metastatic burden too, in a LOX-dependent breast tumor transgenic mouse model. In our current study, we present the medicinal chemistry development leading to the discovery of the orally efficacious AMT inhibitor **9f**.














RESULTS AND DISCUSSION

LOX Inhibition, Initial SAR. We ran a high-throughput screen (HTS) at Evotec, of 267 000 diverse compounds and 5000 fragments, on LOX, which yielded a hit rate of 0.4%. (5-(Piperidin-1-ylsulfonyl)thiophen-2-yl)methanamine **2a** was identified as a positive hit with a mean IC_{50} of 19 μM . Since no crystal structure of LOX is available, the design of inhibitors could not be aided by crystallographic or in silico methods. Therefore, the SAR of enzyme inhibition is largely elucidated by introducing systematic modifications to different regions of the hit molecule.

Substitutions at the 5-Sulfonyl Linker, Sulfonamides. SAR exploration commenced with the investigation of sulfonamide substitutions on LOX inhibition (Table 1). Acyclic sulfona-

Table 1. Effects of Sulfonamide Substitution on LOX Potency



R	LOX IC_{50} (μM) ^a	R	LOX IC_{50} (μM) ^a
	17, 21		2.5, 2.7
	70, 72		20, 25
	27, 31		9.4, 12.7
	11, 13		3.1, 3.1
	3.1, 3.3		2.1 [1.3, 3.2]
	3.8, 3.8		0.93 [0.74, 1.17]
	1.9 [1.2, 3.1]		


^aReported IC_{50} values were determined in at least two separate experiments ($n \geq 2$). When $n = 2$, individual IC_{50} values are shown. When $n > 2$, the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval of the geometric mean.











mides show no improvement (**2b** and **2c** vs **2a**), whereas 2-amido- and 2-hydroxymethylpyrrolidine substitutions exhibit comparable or better LOX potencies (**2d** and **2e** vs **2a**). 2-Phenylpyrrolidine **2f** is also effective against LOX, as is the bicyclic indoline **2g**, which is ~ 10 -fold more potent than the piperidine hit **2a**. Similarly, tetrahydroquinoline **2h** is equipotent to indoline **2g**. Replacement of the piperidine ring with morpholine does not improve LOX inhibition (**2i** vs **2a**), whereas homopiperazine (**2j**) substitution leads to ~ 2 -

fold improvement in IC_{50} . Functionalization of the free homopiperazine nitrogen with small groups leads to gains in potency compared with the initial hit, as exemplified in *N*-methyl analogue **2k**, ethyl urea **2l** and, in particular, sulfonamide **2m**.

Substitution at the 5-Sulfonyl Linker, Sulfones. The effect of alkyl and aryl substitutions at the 5-sulfonyl linker on LOX inhibition was investigated next (Table 2). Replacements of

Table 2. Effects of Sulfonyl-Alkyl and -Aryl Substitutions on LOX Potency
















R	LOX IC_{50} (μM) ^a	R	LOX IC_{50} (μM) ^a
	2.1 [0.65, 7.1]		4.7 [3.3, 6.8]
	1.7 [1.4, 2.2]		0.69 [0.093, 5.1]
	2.3 [1.2, 4.1]		2.8 [1.8, 4.4]
	0.89, 1.3		0.26 [0.15, 0.44]
	5.5, 7.3		12, 13

^aReported IC_{50} values were determined in at least two separate experiments ($n \geq 2$). When $n = 2$, individual IC_{50} values are shown. When $n > 2$, the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval of the geometric mean.

the piperidine moiety on HTS hit **2a** with cyclohexyl (**3a**) and phenyl groups (**3b**) are beneficial, as are pyridine (**3c**) and thiophene (**3d**). Biphenylsulfone is a weaker inhibitor than the phenyl analogue (**3e** vs **3b**), whereas 2-naphthalylsulfone **3g** is more potent than the 1-regioisomer **3f**. Methanesulfonamidophenyl analogue **3h** moderately inhibits LOX, whereas methanesulfonylphenyl sulfone **3i** is an excellent LOX inhibitor with an IC_{50} of 0.26 μM , ~ 70 -fold more potent than the HTS hit **2a**. Replacement of the phenyl moiety of inhibitor **3i** with an alkyl group (**3j**) leads to a reduction in potency. The SAR data illustrate that the attachment of cyclic alkyl or aryl groups to the sulfonyl linker greatly improves LOX potency and the inhibitory effect is further enhanced by the addition of a second sulfonyl group.

Modification of the 5-Sulfonyl Linker. The impact of the sulfonyl linker was subsequently examined (Table 3). A noticeable correlation can be observed between the electron-withdrawing ability of the linker and the LOX IC_{50} , with the most electron-withdrawing sulfonyl group achieving the most potent inhibition (LOX IC_{50} : **3b** < **4a** < **4b**). Carboxamide substitution does not improve LOX inhibition (**4d** vs **4c**). Finally, exchanging the sulfonyl linker and the phenyl ring leads to reduction in potency (**4e** vs **3b**). It is thus apparent that the sulfonyl moiety is the optimum linker for the AMT core and that the electron-withdrawing effect of the linker is likely to play an important role in the mechanism of inhibition even though the possibility of H-bond and dipole–dipole interactions cannot be ruled out.














Table 3. Effects of Sulfonyl Linker (X) Modification on LOX Potency


	X	R	LOX IC ₅₀ (μM) ^a
3b			1.7 [1.4, 2.2]
4a			6.9 [5.6, 8.6]
4b			14, 27
4c			15, 15
4d			20, 25
4e			13 [7.4, 22]

^aReported IC₅₀ values were determined in at least two separate experiments ($n \geq 2$). When $n = 2$, individual IC₅₀ values are shown. When $n > 2$, the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval of the geometric mean.

Modification of the Thiophene Ring. Aminomethylene-pyridine **5a** is ~10-fold weaker than the aminomethylenethiophene counterpart (Table 4; **5a** vs **5b**). 1,4-Thiazole **5c** is considerably less potent as an inhibitor than the 1,3-regiomers **5d**, whereas 1,3-thiazole **5d** demonstrates potency that is similar to the thiophene **3g**. Furan replacement does not


Table 4. Effects of Thiophene Modifications on LOX Potency













	R	LOX IC ₅₀ (μM) ^a
		5a 25, 25
		5b 1.5 [0.47, 4.5]
		5c 24, 27
		5d 1.0, 1.2
		3g 0.69 [0.093, 5.1]
		5e 40, 45
		4d 20, 25
		2g 1.9 [1.2, 3.1]
		5f 12, 13

^aReported IC₅₀ values were determined in at least two separate experiments ($n \geq 2$). When $n = 2$, individual IC₅₀ values are shown. When $n > 2$, the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval of the geometric mean.

improve the effectiveness of the inhibitors (**5e** vs **4d**). Additional substitutions on the thiophene ring can potentially be a useful handle for the development of the series, but the introduction of a small methyl group is highly unfavorable (**5f** vs **2g**). Overall, although the replacements of the thiophene core with some unsubstituted 5-membered heterocycles are tolerated for LOX inhibition, they are not superior to thiophene itself.

Modification of the Aminomethylene Moiety. All inhibitors contain the aminomethylene moiety (H₂NCH₂), which forms a part of the core AMT scaffold. We therefore investigate a series of modifications to this group where the replacement moieties are sufficiently diverse for probing noncovalent interactions, such as H-bond, electrostatic, and dipolar interactions, while small enough to minimize unfavorable steric clashes. The SAR data reveals that all substitutions or modifications at this site result in total loss of activity (Table 5,

Table 5. Effects of Aminomethylene Modifications (R¹) on LOX Potency


Compound	R ¹	R ²	LOX IC ₅₀ (μM) ^a
6a			>100, >100
6b			>100, >100
6c			>100, >100
6d			>100, >100
6e			>100, >100
6f			>100, >100

^aReported IC₅₀ values were determined in at least two separate experiments ($n \geq 2$). When $n = 2$, individual IC₅₀ values are shown. When $n > 2$, the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval of the geometric mean.

6a–6f). It is thus apparent that the aminomethylene moiety has a unique role in LOX inhibition; it is likely to be involved in the formation of a Schiff base similar to that of the natural lysyl substrates.


Next, regioisomers on the thiophene ring were investigated (Table 6). Both 2-aminomethyl-3-sulfonyl-thiophene **7a** and 3-aminomethyl-4-sulfonylthiophene **7b** show no inhibitory activity against LOX, whereas 2-aminomethyl-4-sulfonylthiophene **7c** is a weak inhibitor. Therefore, from these modifications, the thiophene ring is the optimal ring type and the aminomethylene and sulfonyl groups are the most effective substituents when placed on the 2- and 5-positions of the ring, respectively.

Although the exact mode of binding of these AMT inhibitors remains unclear due to the absence of a cocrystal structure or a homology model, the observed SAR suggests that a stable Schiff base formed from the inhibitor and the LTQ cofactor (Figure 2) is likely to be involved. Although the formation of

Table 6. Effects of Regioisomers on the Thiophene Ring on LOX Potency

	R		LOX IC ₅₀ (μM) ^a
		3g	0.69 [0.093, 5.1]
		7a	>100, >100
		7b	>100, >100
		7c	11 [8.0, 18]

^aReported IC₅₀ values were determined in at least two separate experiments ($n \geq 2$). When $n = 2$, individual IC₅₀ values are shown. When $n > 2$, the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval of the geometric mean.

**Figure 2.** Proposed binding mode of AMT inhibitors.

the Schiff base is reversible, its stabilization by the sulfonyl substituent on the thiophene ring by resonance stabilization and/or direct binding to the enzyme by noncovalent processes, such as H-bonding, electrostatic, dipolar, or van der Waals interactions, can lead to a tightly bound enzyme–inhibitor complex. This can potentially rationalize the improvement in potency observed in Table 3. The SAR also suggests an

additional noncovalent interaction between the methanesulfonylphenyl moiety and the enzyme, which further enhances the potency of bis-sulfonyl inhibitors such as compound **9f**.

Optimization toward In Vivo-Compatible Inhibitors.

As our aim is to discover LOX inhibitors that can be administered orally, metabolic stability and pharmacokinetic (PK) studies were performed on the most promising AMT inhibitors described above. The highly potent bis-sulfonylphenyl analogue **3i** has good stability against mouse microsomal (MLM) degradation (Table 9), but its poor detectability by mass spectrometry renders it unsuitable for in vivo studies. Bis-sulfonylhomopiperazine **2m** also exhibits good anti-LOX potency, but it cannot be progressed further due to poor stability against microsomal metabolism. Naphthalenesulfone **3g** demonstrates good MLM stability but only moderate plasma exposure (AUC = 4.2 μM h) when administered orally in mice at 50 mg/kg. It was apparent that further medicinal chemistry development was necessary to achieve both potent LOX inhibition and oral plasma drug exposure compatible with in vivo studies.

Due to its superior LOX potency and ease of synthesis, inhibitor **3i** was chosen as the platform for the next phase of discovery. Initial SAR established that modifications of the aminomethylene group, the thiophene ring, and the sulfonyl linker were unfavorable to target inhibition. Therefore, optimization to improve PK properties focused on the aryl ring and its side-chain substituents. The aim of the subsequent studies therefore targeted improvement to oral in vivo PK exposure whilst maintaining/improving LOX potency.


Side-Chain Substitutions. Further SAR studies began with the investigation of the sulfonyl side-chain substitutions (Table 7). The attachment of the sulfonyl side chain through the 3-position (with respect to the thiophene sulfone) affords inhibitors with similar LOX IC₅₀s as the 4-regioisomers (**8a** vs **3i**, **8d** vs **8c**), whilst 2-substitution is disfavored (**8b** vs **3i**). Sulfonylpyrrolidines exhibit similar potencies as the methyl sulfone counterparts (**8c–8e** vs **3i** and **8a**), but phenyl sulfone

Table 7. Effects of Side-Chain Substitutions on LOX Potency of Phenylsulfonyl-AMT Analogues

Compound	Position of R	Structure of R	LOX IC ₅₀ (μM) ^a	Compound	Position of R	Structure of R	LOX IC ₅₀ (μM) ^a
3i	4		0.26 [0.15, 0.44]	8f	4		1.6, 2.0
8a	3		0.39 [0.27, 0.58]	8g	4		0.29 [0.11, 0.78]
8b	2		1.4 [1.2, 1.7]	8h	4		0.44, 0.46
8c	4		0.92 [0.78, 1.1]	8i	4		0.59 [0.47, 0.73]
8d	3		0.61 [0.48, 0.77]	8j	4		0.72 [0.58, 0.91]
8e	3		0.42 [0.34, 0.53]	8k	4		1.3, 2.1

^aReported IC₅₀ values were determined in at least two separate experiments ($n \geq 2$). When $n = 2$, individual IC₅₀ values are shown. When $n > 2$, the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval.

Table 8. Effects of 5-Substitutions on LOX Potency of Bis-sulfonylphenyl-AMT Analogues

















Compound	Position of 	R	LOX IC ₅₀ (μM) ^a	Compound	Position of 	R	LOX IC ₅₀ (μM) ^a
9a	3		1.2 [0.88, 1.75]	9g	3		1.1 [0.75, 1.62]
9b	3		1.9 [1.5, 2.3]	9h	3		3.7 [1.7, 8.2]
9c	3		2.5 [1.6, 3.9]	9i	3		6.5 [3.9, 11]
9d	3		1.7 [1.56, 1.75]	9j	4		0.71, 0.76
9e	3		1.4, 1.7	9k	4		0.80, 0.81
9f	3		0.90 [0.55, 1.48]	9l	4		0.76, 0.86

Table 9. In Vitro Mouse Liver Microsome (MLM) Stability and in Vivo Pharmacokinetic (PK) Properties of AMT Inhibitors

compound	MLM stability (%) ^a	C _{max(PO)} (μM) ^b	AUC _(PO) (μM h) ^c	CL _(IV) (mL/(min kg)) ^d	t _{1/2(IV)} (h) ^e	F (%) ^f
2m	37					
3i	67	ND	ND			
8j	91	0.38	0.36			
8d	59	0.83	0.22			
8e	63	1.5	0.46			
9k	41	1.6	1.4			
9b	67	6.3	2.3			
9j	90	9.6	2.8			
3g	100	15	4.2			
9a	68	16	6.5			
9g	60	6.7	11	67	1.0	39
9l	95	9.4	12	106	0.4	74
9f	65	17	15	49	1.2	45

^aMouse liver microsome (MLM) stability values represent the percentage of compound remaining after 30 min; mouse plasma PK parameters were determined following a single dose by oral gavage (PO) or intravenous injection (IV) at 50 or 10 mg/kg, respectively. ^bC_{max}: maximum concentration. ^cAUC: area under curve. ^dCL: clearance. ^et_{1/2}: half-life. ^fF: bioavailability; ND: could not be detected by MS.

8f is a weaker inhibitor. Small alkyl substituents on the sulfonyl group are generally well tolerated (**8g–8k**). Inhibitors **8d**, **8e**, and **8j** show good anti-LOX potency and MLM stability (Table 9) and were thus selected for in vivo PK evaluation. Unfortunately, they have poor plasma exposure in mice when dosed orally.

Phenyl Ring Substitution. 1,3- and 1,4-Bis-sulfonylphenyl-AMT inhibitors containing an additional substituent on the 5-position of the phenyl ring were evaluated against LOX inhibition (Table 8). All of *tert*-butyl, *tert*-butoxy, trimethylsilylethynyl, *N*-methylpyrazolyl, and pyridinyl substitutions on the 1,3-bisulfonylphenyl motif lead to moderate reduction in LOX potency (**9a–9e** vs **8a**), whereas a phenyl substituent is well tolerated (**9f**). Replacement of the phenyl group with *p*-tolyl affords an equipotent LOX inhibitor (**9g** vs **9f**), but *m*-xylyl (**9h**) and *o*-ethylphenyl (**9i**) substitutions are disfavored. For the 1,4-bis-sulfonylphenyl-AMT motif, all of the *N*-

methylpyrazolyl (**9j**), phenyl (**9k**), and *p*-tolyl (**9l**) analogues exhibit sub-micromolar LOX IC₅₀ values.

In vivo mouse PK studies were then conducted for selected 5-substituted compounds. Both *tert*-butoxy (**9b**) and *N*-methylpyrazolyl (**9j**) analogues exhibit low AUCs of 2.3 and 2.8 μM h, respectively (Table 9), although this improves to 6.5 μM h when the oxygen atom of the *tert*-butoxy group is removed from the parent compound (**9a** vs **9b**). Pleasingly, the 5-*p*-tolyl-substituted bis-sulfones have greatly improved and therapeutically relevant plasma exposures (11 and 12 μM h for **9g** and **9l** respectively) are obtained. Although the exposure for 5-phenyl-1,4-bis-sulfone **9k** is disappointing (AUC = 1.4 μM h), 5-phenyl-1,3-bis-sulfonyl-AMT **9f** achieves a desirable in vivo PK profile, with the highest AUC, C_{max}, longest half-life, lowest clearance of the series (albeit this is still moderate), and a respectable intermediate oral bioavailability (*F*) of 45%.

Table 10. Potency, Selectivity, and Permeability of Optimized AMT Inhibitors

inhibitor	LOX IC ₅₀ (μM) ^a	LOXL2 IC ₅₀ (μM) ^a	DAO IC ₅₀ (μM) ^a	SSAO IC ₅₀ (μM) ^a	MAO-A MAO-B IC ₅₀ (μM) ^a	hERG IC ₅₀ (μM)	Caco-2 P _{app} ^b (10 ⁻⁶ cm/s)	
							A → B	B → A
9g	1.1 [0.75, 1.62]	2.0 [1.3, 3.0]	>100, >100	49, 59	A: >100, >100 B: 87, 89	4.6	8.0	17
9l	0.76, 0.86	2.2 [1.4, 3.7]	>100, >100	>100, 100	A: 33, 33 B: >100, >100	68	18	25
9f	0.90 [0.55, 1.48]	1.5 [0.28, 8.1]	>100, >100	48, 90	A: >100, >100 B: >100, >100	25	8.5	35

^aReported IC₅₀ values were determined in at least two separate experiments ($n \geq 2$). When $n = 2$, individual IC₅₀ values are shown. When $n > 2$, the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval of the geometric mean.
^bP_{app}: permeability coefficient.

Profile of Orally Available AMT Inhibitors. We have discovered three AMT inhibitors **9g**, **9l**, and **9f** that are highly effective in inhibiting LOX activity as well as possessing therapeutically relevant PK profiles. These compounds are equally potent inhibitors of LOXL2 (Table 10), which is as expected due to the highly conserved catalytic site across the LOX-family members. Pleasingly, all three inhibitors are inactive against common amine oxidases, including the copper-containing diamine oxidase (DAO), semicarbazide-sensitive amine oxidase (SSAO), and the flavin-containing monoamine oxidases (MAO) A and B. It is noteworthy that AMT **9f** is a substrate of SSAO; thus, SSAO-catalyzed metabolism could be a potential mechanism of degradation in vivo.

AMT **9g** is a weak inhibitor of the human potassium-ion channel hERG, whereas inhibitors **9l** and **9f** are highly selective. All three inhibitors exhibit high permeability through colon Caco-2 cells, which is reflected in their good oral availabilities in mice (Table 9). AMT inhibitor **9f** achieves the most favorable overall profile and was therefore chosen for in vivo efficacy studies.

Evaluation of Anti-metastatic Efficacy. Compound **9f** was assessed in a LOX-driven genetically engineered mouse model (GEMM) of breast cancer that metastasizes to the lungs.¹⁹ Mice were dosed daily by oral gavage (70 mg/kg) from day 60 when primary tumors start to be palpable (Figure 3). The metastatic nodules in the lungs are measured when the primary tumors reach an ethical size limit. Pleasingly,





Figure 3. Anti-metastatic efficacy of compound **9f** in LOX-driven GEMM model. Animals treated with vehicle (black) or compound **9f** at 70 mg/kg qd (blue). All values are reported as the arithmetic mean with the error expressed as the standard error of the means. (A) Number of lung metastasis, vehicle, $n = 7$; **9f** treated, $n = 5$; (B) Lung metastasis area in μm^2 , vehicle, $n = 7$; **9f** treated, $n = 5$.

compound **9f** reduces lung metastasis significantly, as measured by the total surface area (Figure 3B).

SYNTHETIC CHEMISTRY

AMT-Sulfonamides. All sulfonamide analogues were synthesized from the sulfonyl chloride intermediates **11a** and **11b** by condensation with the corresponding amines in dichloromethane (DCM) (Scheme 1). Subsequent trifluor-


Scheme 1. General Synthetic Routes to AMT-Sulfonamide Analogues **2a–n** and **5f**^a



^aReagents and conditions: (a) TFAA, Et₃N, DCM, room temperature (rt); (b) ClSO₃H, DCM, -78°C to rt, then H₂O; (c) oxalyl chloride, dimethylformamide (DMF), DCM, rt; (d) R₂NH, Et₃N, DCM, rt; (e) aq. NaOH, MeOH, rt or 7 N NH₃ in MeOH, rt; (f) *N*-Boc-homopiperazine, Et₃N, DCM, rt; (g) 2 M HCl in Et₂O, rt; (h) R'-Cl (EtNCO for **2l**), Et₃N, DCM, rt.

oacetamide hydrolysis or methanolysis using aqueous NaOH or 7 N NH₃ in methanol furnishes the desired amines **2a–2i**. 3-Methylthiophene sulfonamide **5f** (Table 4) was also synthesized by this method. Sulfonyl chlorides **11a** and **11b** were derived from the commercially available thiophen-2-ylmethanamines **10a/10b** in straightforward steps. Access to sulfonylhomopiperazine analogues with additional functionalization at the free amino group could be achieved via the amine hydrochloride intermediate **12**, where *N*-substituted sulfonylhomopiperazines **2k**, **2l**, and **2m** were obtained in three steps. The unsubstituted sulfonylhomopiperazine **2j** was synthesized from sulfonyl chloride **11a** by condensation with *N*-Boc-homopiperazine and trifluoroacetamide hydrolysis, followed by Boc removal.


AMT-Sulfones. Synthesis of 2-pyridinesulfonyl **3c** proceeded by the lithiation of 2-methylthiophene **14** followed by condensation with aldrithiol-2 to afford the corresponding sulfide, which underwent S-oxidation with mCPBA to afford sulfone **15** (Scheme 2). Subsequent methyl bromination was followed by the displacement of the bromide by sodium azide to give the resulting alkyl azide, which was catalytically

Scheme 2. Synthetic Routes to AMT-Sulfone Analogues 3c and 3j^a

^aReagents and conditions: (a) ^tBuLi, tetrahydrofuran (THF), -40 °C, then aldrithiol-2, -40 °C to rt; (b) mCPBA, DCM, rt; (c) NBS, Bz₂O₂, 1,2-dichloroethane (DCE), 70 °C; (d) NaN₃, DMF, rt; (e) H₂, Pd/C, THF, rt; (f) ^tBuLi, THF, -40 °C, then 1,2-dithiane, -40 °C to rt, then MeI, rt.

hydrogenated to afford the desired 2-pyridinesulfonyl-AMT 3c. Similarly, ring opening of 1,2-dithiane with lithiated 2-methylthiophene followed by condensation with iodomethane afforded the corresponding bis-sulfide, which underwent subsequent S-oxidation to afford bis-sulfone 16. This intermediate was subsequently converted to bis-sulfonylbutyl-AMT 3j by the method described above.


The commercially available 5-bromo-2-thiophenecarbonitrile 17a (interchangeable with 5-chloro-2-thiophenecarbonitrile) and 2-bromothiazole-5-carbonitrile 17b served as valuable building blocks for the AMT-sulfone inhibitors (Scheme 3). Nucleophilic aromatic substitution with a range

Scheme 3. Synthetic Routes to AMT-sulfone Analogues 3a, 3b, 3d–3i, 5b, 5c, 8a, 8b, and 9b^a

^aReagents and conditions: (a) RSH, K₂CO₃, DMF, heat; (b) mCPBA, DCM, rt; (c) BH₃·THF, THF, rt; (d) MsCl, Et₃N, DCM, rt; (e) Boc₂O, Et₃N, DCM, rt; (f) 4 M HCl in dioxane, rt.

of thiols afforded the corresponding sulfides, which were oxidized with mCPBA to afford sulfone intermediates 18. Subsequent nitrile reduction with borane–tetrahydrofuran complex afforded AMT-sulfones 3a, 3b, 3d, 3f, 3g, 3i, 5b, 8a, 8b, and 9b. For sulfonylaniline 3h, the product from the initial condensation 19 underwent an additional sulfonamide formation step. Subsequent mCPBA-mediated oxidation afforded the usual sulfone intermediate 18, which was converted to the desired target. Analogues 3e and 5c were synthesized from carbamates 20, which were derived from nitriles 17a and 17b, respectively, by condensation with the corresponding thiols, followed by nitrile reduction and subsequent Boc protection.

Sulfonamide-substituted phenylsulfonyl-AMT analogues 8c–8e were synthesized from the corresponding thiols 22 (Scheme 4). Hence, condensation of 3- or 4-fluorophenylsul-

Scheme 4. Synthetic Route to Sulfonamide-Substituted Phenylsulfonyl-AMTs 8c–8e^a


^aReagents and conditions: (a) HNR₂, DCM; (b) NaSMe, DMF, 165 °C; (c) 5-chloro-2-thiophenecarbonitrile, K₂CO₃, DMF, 120–130 °C; (d) BH₃·THF, THF, rt; (e) TFAA, Et₃N, DCM; (f) mCPBA, DCM, rt; (g) 7 N NH₃ in MeOH, rt.

fonyl chloride 21 with the desired amines (HNR₂) afforded the corresponding sulfonamides, which were thiolated by treatment with sodium thiomethoxide to afford intermediate thiols 22. The thiols were condensed with 5-chloro-2-thiophenecarbonitrile to yield sulfides 23. The nitrile group of sulfides 23 was then converted to the corresponding trifluoroacetamide by nitrile reduction and amide formation. S-oxidation of sulfides 24 and subsequent amine deprotection affords the desired AMT targets 8c–8e.


The sulfonyl side chains of AMT analogues 8g–8k were introduced through the nucleophilic substitution of the chlorine atom on intermediate 26 (Scheme 5), which could be obtained in straightforward steps using methods previously described in Scheme 3. Condensation of intermediate 26 with 2-mercaptoethanol or 3-mercaptoopropanol followed by sulfide oxidation led to alkanol intermediates 27. After Boc removal, these intermediates afforded AMT targets 8g and 8h. Alternatively, treatment of hydroxyethylsulfone 27 (*n* = 1) with methanesulfonyl chloride led to concomitant sulfonylation and elimination, furnishing vinyl sulfone 28. Addition of pyrrolidine to vinyl sulfone 28 followed by Boc removal gives AMT target 8i. Ammonia addition to intermediate 28 provided the corresponding aminoethyl sulfone, which was treated with acetic anhydride to afford the corresponding AMT-acetamide 8j after Boc removal. Methoxyethylsulfone 8k was also obtained by from vinyl sulfone 28 by methoxide addition followed by Boc removal.

Phenyl sulfide 29, obtained from methods previously described in Scheme 3, underwent a Friedel–Crafts sulfonylation to afford the corresponding phenylsulfonyl (Scheme 6), which was subsequently oxidized to bis-sulfone 30 using mCPBA. Reduction of the nitrile group with borane–tetrahydrofuran complex afforded the bis-sulfonylphenyl-AMT analogue 8f.


tert-Butyl-bis-sulfonylphenyl-AMT 9a was synthesized from 1,3-dibromo-5-(*tert*-butyl)benzene 31 (Scheme 7). *tert*-Butyllithium-mediated lithium-bromine exchange of dibromide 31 and treatment of the resultant lithium phenylate with dimethyl disulfide afforded the corresponding methyl sulfide, which was oxidized to sulfone 32 using mCPBA. This underwent Pd-catalyzed cross coupling with thiophene-2-thiol to yield the corresponding thiophene sulfide, which was formylated under Vilsmeier–Haack conditions to give aldehyde 33. After

Scheme 5. Synthetic Routes to Phenylsulfonyl-AMTs with Sulfonyl Side-Chain Modifications (8g–8k)^a

^aReagents and conditions: (a) 2-mercaptoethanol or 3-mercaptoopropanol, K_2CO_3 , DMF, 50 °C; (b) mCPBA, DCM, rt (45–61% over two steps); (c) 4 M HCl in dioxane, rt; (d) MsCl, Et_3N , DCM, rt (quant.); (e) pyrrolidine, DCM, rt (85% for steps e + c); (f) 7 N NH_3 in MeOH, rt; (g) Ac_2O , Et_3N , DCM, rt; (h) K_2CO_3 , MeOH, rt.

Scheme 6. Synthetic Route to Bis-sulfonylphenyl-AMT 8f^a

^aReagents and conditions: (a) $PhSO_2Cl$, $FeCl_3$, neat, 100 °C; (b) mCPBA, DCM, rt (c) $BH_3 \cdot THF$, THF, rt.


Scheme 7. Synthetic Route to *tert*-Butyl-bis-sulfonylphenyl-AMT 9a^a

^aReagents and conditions: (a) $tBuLi$, THF, –78 °C then MeSSMe, –78 °C to rt; (b) mCPBA, DCM, rt; (c) thiophene-2-thiol, $Pd_2(dba)_3$, xantphos, K_2CO_3 , *p*-xylene; 140 °C; (d) $POCl_3$, DMF, 50 °C; (e) $NaBH_4$, THF, rt; (f) DPPA, PPh_3 , diisopropyl azodicarboxylate, THF, rt; (g) H_2 , Pd/C, EtOH, rt.

reduction of the aldehyde with sodium borohydride and subsequent sulfide oxidation, the hydroxyl group was substituted with azide using diphenyl phosphoryl azide (DPPA) before it was subsequently reduced to the desired AMT target 9a.

5-Substituted 1,3-bis-sulfonylphenyl-AMTs 9c–9i were synthesized from aryl bromide 34.¹⁹ Hence, Pd-catalyzed cross coupling of aryl bromide 34 with trimethylsilylacetylene under Sonogashira conditions afforded the corresponding aryl-


alkyne (Scheme 8), which was subjected to HCl-mediated Boc deprotection to afford AMT analogue 9c. The Suzuki–

Scheme 8. Synthetic Routes to Substituted Bis-sulfonylphenyl-AMTs 9c–9i^a

^aReagents and conditions: (a) $Pd(PPh_3)_4$, CuI, Et_3N , trimethylsilylacetylene, dioxane, rt; (b) 4 M HCl in dioxane, DCM, rt; (c) $Pd(PPh_3)_4$, $RB(OR')_2$, Cs_2CO_3 , dioxane, 100 °C.

Miyaura coupling with boronic acids gave the corresponding biaryl products, which underwent Boc removal to furnish the desired AMT inhibitors 9d–9i.

5-Substituted 1,4-bis-sulfonylphenyl-AMTs 9j–9l were synthesized from bromofluorobenzene intermediate 36 (Scheme 9), which could be obtained from the commercially available 5-bromothiophene-2-carbonitrile 17a and 3-bromo-4-fluorobenzenethiol 35 by methods previously described in Scheme 3. Selective substitution of the fluorine atom of

Scheme 9. Synthetic Routes to Substituted Bis-sulfonylphenyl-AMTs 9j–9l^a

^aReagents and conditions: (a) NaSMe, DMF, rt; (b) mCPBA, DCM, rt; (c) Pd(PPh₃)₄, RB(OR')₂, Cs₂CO₃, dioxane, 100 °C; (d) 4 M HCl in dioxane, DCM, rt.

intermediate **36** with thiomethoxide afforded the corresponding sulfide, which was oxidized to sulfone **37** using mCPBA. The Suzuki–Miyaura coupling with boronic acids and subsequent Boc removal furnished the desired AMT inhibitors **9j–9l**.


AMT-Sulfide, AMT-Sulfoxide, and Aminomethylene Modifications. AMT-sulfide **4b** and AMT-sulfoxide **4a** (Scheme 10) were derived from intermediate sulfide **29** (see Scheme 3; R = Ph). Mono S-oxidation of sulfide **29** with 1 equivalent of mCPBA and subsequent nitrile reduction leads to AMT-sulfoxide **4a**. Reduction of intermediate **29** with borane–tetrahydrofuran complex, followed by Boc protection affords carbamate **38**. Removal of Boc from carbamate **38** led to AMT-sulfide **4b**, whereas N-methylation using sodium hydride/iodomethane and subsequent oxidation with mCPBA affords intermediate **39**, which was deprotected to afford the N-methyl AMT analogue **6a**. Alternatively, sulfone **6c** can be obtained from the condensation of bromothiophene **17a** and sodium benzenesulfinate in DMF. This intermediate was converted to the corresponding thiopheneacetimidamide **6d**

and thiophenecarboxamide **6e** by treatment with indium trichloride (InCl₃) and lithium hexamethyldisilazide (LiHMDS), respectively.


Condensation of 1-(5-chlorothiophen-2-yl)ethan-1-one **40** with thiophenol afforded the corresponding sulfide (Scheme 11), which was oxidized to sulfone **41** using mCPBA. Subsequent oxime formation followed by reduction using zinc powder in trifluoroacetic acid furnished C-methylated AMT **6b**. Sulfide **42** was obtained in straightforward steps by methods previously illustrated in Scheme 3. Oxidation of sulfide **42** with mCPBA afforded the corresponding sulfone **43**. This was reduced to the corresponding aldehyde with DIBAL-H before conversion to oxime **6f** by treatment with hydroxylamine hydrochloride.

AMT- and Aminomethylenefuran-amides. Synthesis of AMT-amide **4d** and aminomethylenefuran-amide **5f** were accomplished via methyl esters **44** (Scheme 12; A = S or O).^{20,21} Esters **44** first underwent saponification with aqueous hydroxide, and the resultant carboxylic acids were then converted to acid chlorides **45** using oxalyl chloride. Condensation with benzylamine in dichloromethane followed by catalytic hydrogenation using 10% Pd/C in tetrahydrofuran furnished the desired amides **4d** and **5e**.


Aminomethylene-pyridine, Aminomethylene-1,3-Thiazole, and Aminomethylene-Imidazole. Aminomethylene-pyridine **5a** was obtained from the commercially available *tert*-butyl ((6-chloropyridin-3-yl)methyl)carbamate **46**. Condensation with sodium benzylthiolate afforded the corresponding sulfide **47** (Scheme 13). Sulfide oxidation with mCPBA and subsequent HCl-mediated Boc removal furnished the desired target **5a**. 2-(Aminomethylene)-1,3-thiazole **5d** was obtained from sulfide intermediate **49** in a similar manner. Sulfide **49** was synthesized from *tert*-butyl ((5-bromothiazol-2-yl)methyl)carbamate²² **48** and naphthalene-2-thiol by a Pd-catalyzed cross-coupling reaction.

Scheme 10. Synthetic Routes to Compounds 4a, 4b, 6a, 6c–6e^a


^aReagents and conditions: (a) mCPBA (2 equiv), DCM, rt; (b) mCPBA (1 equiv), DCM, rt; (c) BH₃·THF, THF, rt; (d) InCl₃, acetaldoxime, toluene, reflux; (e) LiHMDS, Et₂O, rt, then 2 M HCl, rt; (f) Boc₂O, Et₃N, DCM, rt; (g) NaH, MeI, THF, rt; (h) 4 M HCl in dioxane, DCM, rt; (i) sodium benzenesulfinate, DMF, 135 °C.

Scheme 11. Synthetic Routes to Compounds 6b and 6f^a

^aReagents and conditions: (a) thiophenol, K_2CO_3 , DMF, 120 °C; (b) mCPBA, DCM, rt; (c) $H_2NOH \cdot HCl$, *N,N*-diisopropylethylamine (DIPEA), EtOH, rt; (d) Zn, TFA, rt; (e) DIBAL-H, DCM, 45 °C; (f) $H_2NOH \cdot HCl$, K_2CO_3 , EtOH, 70 °C.


Scheme 12. Synthetic Routes to Amide Analogues 4d and 5e^a

^aReagents and conditions: (a) 1 M NaOH, MeOH, rt; (b) $(COCl)_2$, DMF, DCM, rt; (c) benzylamine, DCM, rt; (d) H_2 , Pd/C, THF, rt.

Scheme 13. Synthetic Routes to Aminomethylene-Pyridine, Aminomethylene-Thiazole, and Aminomethylene-Imidazole 5a and 5d^a

^aReagents and conditions: (a) NaH, benzylmercaptan, DMF, 70 °C; (b) mCPBA, DCM, rt; (c) 2 M HCl in Et₂O or 4 M HCl in dioxane, rt; (d) $Pd_2(dba)_3$, xantphos, naphthalene-2-thiol, NaO^tBu, ^tBuOH/toluene, 100 °C.

AMT-Sulfone Regioisomers. The AMT regioisomers 7a–7c were synthesized by two different methods (Scheme 14).


Scheme 14. Synthetic Routes to AMT Regioisomers 7a–7c^a

^aReagents and conditions: (a) naphthalene-2-thiol, K_2CO_3 , DMF, 120 °C; (b) mCPBA, DCM, rt; (c) $BH_3 \cdot THF$, THF, rt; (d) $Pd_2(dba)_3$, xantphos, naphthalene-2-thiol, NaO^tBu, toluene, 110 °C.

The synthesis of 2,3-regioisomer 7a began with nucleophilic aromatic substitution between 3-bromothiophene-2-carbonitrile 51 and naphthalene-2-thiol. The resultant sulfide underwent subsequent sulfide oxidation followed by nitrile reduction to afford the desired target 7a. The initial nucleophilic aromatic substitution step was replaced with a Pd-catalyzed cross coupling for the synthesis of the 3,4- and 2,4-regioisomers 7b and 7c, starting from bromothiophenes 53

and 55. The resultant sulfides were oxidized to sulfones 54 and 56, which were subsequently converted to the corresponding AMT targets 7b and 7c by nitrile reduction.

Finally, the Suzuki–Miyaura coupling between 5-bromo-thiophene-2-carbonitrile 17a and (4-(methylthio)phenyl)-boronic acid 57 affords phenyl thiophene 58 (Scheme 15). This was converted to carbamate 59 by nitrile reduction, Boc protection, and sulfide oxidation. Subsequent Boc removal furnished the phenyl-linked AMT analogue 4e.

Scheme 15. Synthetic Route to Phenyl-Linked AMT 4e^a

^aReagents and conditions: (a) $Pd(PPh_3)_4$, Cs_2CO_3 , 1,4-dioxane, 100 °C; (b) $BH_3 \cdot THF$, THF, rt; (c) Boc_2O , Et₃N, DCM, rt; (d) mCPBA, DCM, rt; (e) 4 M HCl in dioxane, DCM, rt.

CONCLUSIONS

We described herein a series of LOX inhibitors containing a 2-aminomethylene-5-sulfonyl-thiophene core. The attachment of a sulfonylphenyl side chain to the core scaffold via the 5-sulfonyl linker furnishes inhibitors with sub-micromolar LOX IC₅₀ values. Further SAR optimization leads to the discovery of inhibitor **9f** with potent anti-LOX activity as well as desirable selectivity and PK profile, making it a valuable asset for LOX research. More importantly, we have described its ability to reduce the growth of spontaneous breast tumor lung metastasis in a GEMM,¹⁹ thus demonstrating the promise of **9f** as a drug candidate.

EXPERIMENTAL SECTION

Synthesis of Inhibitors. Commercial building blocks, reagents, and solvents for reactions were reagent grade and used as purchased. Flash chromatography was performed on a Biotage Isolera flash purification system using prepacked silica gel cartridges (Biotage) with HPLC grade solvents. Thin-layer chromatography analysis was performed using silica gel 60 F-254 thin-layer plates. Liquid chromatography mass spectrometry (LCMS) and high-resolution mass spectrometry (HRMS) analyses of chemical compounds were performed on an Agilent 1200 series HPLC and a diode array detector coupled to a 6210 time-of-flight mass spectrometer with a multimode ESI source or a Waters Acquity UPLC and diode array detector coupled to a Waters G2 QToF mass spectrometer fitted with a multimode ESI/APCI source. ¹H and ¹³C NMR spectra were recorded on a Bruker Avance 500 MHz or a 300 MHz spectrometer using an internal deuterium lock. NMR data is given as follows: chemical shift (δ) in ppm, multiplicity, coupling constants (J) given in hertz and integration. All final inhibitors submitted for biological evaluation were at least 95% pure by HPLC, apart from compound **2g**, which has a purity of 94%.

General Procedures GP1. Alkylamine was added to a solution of sulfonyl chloride **11a** in DCM, and the reaction mixture was stirred at rt for 1–16 h. One molar HCl was added, and the aqueous phase was extracted with DCM (3 \times). The combined organic layer was dried over MgSO₄ and filtered, and the solvent was removed under reduced pressure. MeOH and aq. NaOH were then added, and the mixture was stirred at rt for 16 h (MeOH and aq. NaOH can be replaced by 7 N NH₃ in MeOH). H₂O was added, and the aqueous phase was extracted with DCM (3 \times). The combined organic phase was dried over MgSO₄ and filtered, and the solvent was removed under reduced pressure to afford the desired AMT-sulfonamide, which could be further purified if necessary.

General Procedures GP2. Four molar HCl in dioxane or 2 M HCl in Et₂O was added to *tert*-butyl carbamate (neat or as a solution in DCM), and the mixture was stirred at rt for 1–16 h. EtOAc was added to precipitate the solids if necessary. The solids were collected by filtration or centrifugation, washed with EtOAc, and dried under vacuum to afford the desired amine hydrochloride. If necessary, this can be further purified by chromatography in its free amine form, which can be obtained by treatment with 7 N NH₃ in MeOH.

General Procedures GP3. BH₃·THF was added to a solution of heteroaryl nitrile in THF, and the mixture was stirred at rt for 1–5 h. EtOH (equal volume to reaction mixture) was then carefully added to quench the reaction. The solution was subsequently heated at 70 °C for 1 h to aid borane decomplexation. The solvent was removed under reduced pressure to afford the desired amine, which could be purified if necessary.

General Procedures GP4. A mixture of 5-bromothiophene-2-carbonitrile **17a** (interchangeable with 5-chorothiophene-2-carbonitrile) or 2-bromothiazole-5-carbonitrile **17b**, alkyl or aryl thiol, K₂CO₃, and DMF was stirred at 50–140 °C. After cooling to rt, the mixture was diluted with EtOAc. The organic phase was washed with 1:1 H₂O/brine (3 \times), dried over MgSO₄, and filtered. The solvent was removed under reduced pressure to afford the desired sulfide product, which could be further purified if necessary.

General Procedures GP5. mCPBA (>2 equiv for sulfones, 1.0 equiv for sulfoxides) was added in small portions to a solution of sulfide in DCM at 0 °C, and the mixture was stirred at rt (0 °C for sulfoxides) for 3–16 h. When complete conversion was achieved, EtOAc was added. The organic phase was washed with sat. NaHCO₃ (3 \times) and sat. Na₂S₂O₃ (until no color was detected on starch iodide paper), dried over MgSO₄, and filtered. The solvent was removed under reduced pressure to afford the desired sulfone/sulfoxide, which could be further purified if necessary.

General Procedures GP6. The alkylamine was dissolved in DCM. Et₃N followed by Boc₂O were added, and the mixture was stirred at rt for 16 h. When complete conversion was achieved, DCM was added. The organic phase was washed with H₂O and brine, dried over MgSO₄, and filtered. The solvent was removed under reduced pressure to afford the desired *tert*-butyl-carbamate, which could be further purified if necessary.

General Procedures GP7. A mixture of aryl bromide, Pd(PPh₃)₄, ArB(OR')₂ (boronic acid or pinacolboronate), Cs₂CO₃, and 1,4-dioxane was degassed with argon and then stirred at 100 °C for 16 h. After cooling to rt, the mixture was filtered through celite and washed with EtOAc. The solvent was removed under reduced pressure to afford the desired biaryl, which could be further purified if necessary.

General Procedures GP8. A mixture of aryl bromide, Pd₂(dba)₃, Xantphos, alkyl or aryl thiol, Na^tBu, and ^tBuOH/toluene (1:4) was degassed with argon and then stirred at 100 °C for 16 h. After cooling to rt, the suspension was filtered through celite and washed with DCM. The solvent was removed under reduced pressure to afford the desired sulfide, which could be further purified if necessary.

(5-(Piperidin-1-ylsulfonyl)thiophen-2-yl)methanamine (2a). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (150 mg, 0.487 mmol), piperidine (96.3 μ L, 0.975 mmol), and DCM (2.4 mL), 16 h, rt and (ii) 1 M NaOH (2 mL) and MeOH (2 mL), rt, 16 h. Compound **2a** was obtained as a white crystalline solid (109 mg, 86%) and did not require further purification. ¹H NMR (500 MHz, chloroform-*d*) δ 7.37 (d, J = 3.6 Hz, 1H), 6.92 (d, J = 3.6 Hz, 1H), 4.20 (br, 2H), 3.11–2.96 (m, 4H), 1.82–1.12 (m, 8H). ¹³C NMR (126 MHz, chloroform-*d*) δ 134.51, 132.45, 123.57, 47.10, 25.23, 23.58. HRMS (ESI) for C₁₀H₁₇N₂O₂S₂ ([M + H]⁺): calculated 261.0726; observed 261.0743; error = 4.8 ppm.

5-(Aminomethyl)-*N,N*-dimethylthiophene-2-sulfonamide (2b). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (100 mg, 0.325 mmol), dimethylamine (40% in H₂O; 0.206 mL, 1.62 mmol), and DCM (1.63 mL), 16 h, rt and (ii) 30% NaOH (0.5 mL) and MeOH (3 mL), rt, 16 h. Compound **2b** was obtained as a white solid (38 mg, 53%) and did not require further purification. ¹H NMR (500 MHz, chloroform-*d*) δ 7.41 (d, J = 3.7 Hz, 1H), 6.95 (dt, J = 3.7, 1.0 Hz, 1H), 4.12 (d, J = 0.6 Hz, 2H), 2.76 (s, 6H), 1.61 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 155.65, 133.60, 132.76, 123.60, 41.66, 38.18. HRMS (ESI) for C₇H₁₃N₂O₂S₂ ([M + H]⁺): calculated 221.0413; observed 221.0409; error = 1.8 ppm.

5-(Aminomethyl)-*N*-ethylthiophene-2-sulfonamide (2c). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (100 mg, 0.325 mmol), ethylamine (2.0 M in MeOH; 0.812 mL, 1.62 mmol), and DCM (1.63 mL), 16 h, rt and (ii) 30% NaOH (0.5 mL) and MeOH (3 mL), rt, 16 h. Compound **2c** was obtained as a colorless oil (23 mg, 32%) and did not require further purification. ¹H NMR (500 MHz, chloroform-*d*) δ 7.46 (d, J = 3.7 Hz, 1H), 6.88 (d, J = 3.7 Hz, 1H), 4.68 (br, 1H), 4.09 (s, 2H), 3.09 (q, J = 7.2 Hz, 2H), 1.76 (br, 2H), 1.15 (t, J = 7.2 Hz, 3H). ¹³C NMR (126 MHz, chloroform-*d*) δ 155.38, 138.81, 132.43, 123.47, 41.60, 38.62, 15.11. HRMS (ESI) for C₇H₁₀NO₂S₂ ([M - NH₂]⁺): calculated 204.1480; observed 204.01460; error = 0.98 ppm.

(S)-1-(5-(Aminomethyl)thiophen-2-ylsulfonyl)pyrrolidine-2-carboxamide (2d). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (75 mg, 0.244 mmol), prolinamide hydrochloride (30.6 mg, 0.268 mmol), Et₃N (74.7 μ L, 0.536 mmol), and DCM (1.2 mL), 16 h, rt and (ii) 1

M NaOH (1.2 mL) and MeOH (1.2 mL), rt, 16 h. The crude was purified by chromatography (1 N NH₃ in MeOH/DCM 0 → 20%) to afford an orange oil (10 mg, 14%). [α]_D²¹ -134.2 (c 0.16, MeOH/CHCl₃). ¹H NMR (500 MHz, methanol-*d*₄) δ 7.58 (d, *J* = 3.8 Hz, 1H), 7.15 (d, *J* = 3.8 Hz, 1H), 4.10 (s, 2H), 4.06 (dd, *J* = 8.3, 4.0 Hz, 1H), 3.61 (ddd, *J* = 10.2, 6.1, 4.6 Hz, 1H), 3.32 (m, 1H), 1.99 (m, 1H), 1.93–1.82 (m, 2H), 1.67 (m, 1H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 177.35, 154.70, 135.83, 134.45, 126.75, 63.79, 50.93, 41.12, 32.07, 25.51. HRMS (ESI) for C₁₀H₁₃N₂O₃S₂ ([M - NH₂]⁺): calculated 273.0362; observed 273.0334; error = 10 ppm.

(S)-(1-(5-(Aminomethyl)thiophen-2-ylsulfonyl)pyrrolidin-2-yl)methanol (2e). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (100 mg, 0.325 mmol), (S)-pyrrolidin-2-ylmethanol (35.3 μ L, 0.358 mmol), Et₃N (100 μ L, 0.715 mmol), and DCM (1.6 mL), 2 h, rt and (ii) 7 N NH₃ in MeOH (5 mL), rt, 20 h. The crude was purified by chromatography (1 N NH₃ in MeOH/DCM 0 → 15%) to afford a yellow oil (47 mg, 52%). [α]_D²¹ -33.6 (c 2.76, MeOH/CHCl₃). ¹H NMR (500 MHz, chloroform-*d*) δ 7.47 (d, *J* = 3.8 Hz, 1H), 6.94 (dt, *J* = 3.7, 1.0 Hz, 1H), 4.11 (d, *J* = 0.8 Hz, 2H), 3.80–3.57 (m, 3H), 3.53–3.45 (m, 1H), 3.30 (dt, *J* = 10.5, 7.1 Hz, 1H), 2.18–1.95 (m, 3H), 1.90–1.69 (m, 3H), 1.60–1.50 (m, 1H). ¹³C NMR (126 MHz, chloroform-*d*) δ 155.82, 134.49, 133.01, 123.57, 65.67, 62.29, 50.22, 41.55, 28.90, 24.41. HRMS (ESI) for C₁₀H₁₇N₂O₃S₂ ([M + H]⁺): calculated 277.0675; observed 277.0629; error = 17 ppm.

(5-(2-Phenylpyrrolidin-1-ylsulfonyl)thiophen-2-yl)methanamine (2f). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (100 mg, 0.325 mmol), 2-phenylpyrrolidine (40.7 mg, 0.357 mmol), Et₃N (100 μ L, 0.715 mmol), and DCM (1.6 mL), 2 h, rt and (ii) 7 N NH₃ in MeOH (4 mL), rt, 16 h. The crude was purified by chromatography (1 N NH₃ in MeOH/DCM 0 → 20%) to afford a brown oil (40 mg, 38%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.42 (d, *J* = 3.7 Hz, 1H), 7.38–7.21 (m, 5H), 6.90 (dt, *J* = 3.7, 1.0 Hz, 1H), 4.80 (dd, *J* = 8.0, 3.6 Hz, 1H), 4.10 (d, *J* = 0.9 Hz, 2H), 3.68 (m, 1H), 3.45 (dt, *J* = 10.5, 7.3 Hz, 1H), 2.04 (m, 1H), 1.96–1.81 (m, 2H), 1.70 (m, 1H), 1.53 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 155.35, 143.01, 135.67, 132.68, 128.44, 127.18, 126.22, 123.38, 63.71, 49.77, 41.57, 35.82, 24.08. HRMS (ESI) for C₁₅H₁₉N₂O₂S₂ ([M + H]⁺): calculated 323.0883; observed 323.0873; error = 3.1 ppm.

(5-(Indolin-1-ylsulfonyl)thiophen-2-yl)methanamine (2g). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (100 mg, 0.325 mmol), indoline (142 mg, 0.358 mmol), Et₃N (100 μ L, 0.715 mmol), and DCM (1.6 mL), 2 h, rt and (ii) 7 N NH₃ in MeOH (5 mL) at rt, for 20 h. The crude was purified by chromatography (1 N NH₃ in MeOH/DCM 0 → 15%) to afford a brown solid (73 mg, 76%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.58 (d, *J* = 8.1 Hz, 1H), 7.42 (d, *J* = 3.8 Hz, 1H), 7.24–7.16 (m, 1H), 7.12 (d, *J* = 7.4 Hz, 1H), 7.00 (td, *J* = 7.4, 0.9 Hz, 1H), 6.88–6.78 (m, 1H), 4.01 (s, 2H), 3.95 (d, *J* = 8.4 Hz, 2H), 2.98 (t, *J* = 8.4 Hz, 2H), 1.56 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 156.23, 141.59, 133.90, 132.97, 131.84, 127.81, 125.24, 124.07, 123.43, 115.10, 50.30, 50.25, 41.51, 27.91. HRMS (ESI) for C₁₃H₁₅N₂O₂S₂ ([M + H]⁺): calculated 295.0569; observed 295.0577; error = 2.7 ppm.

(5-(3,4-Dihydroquinolin-1(2H)-ylsulfonyl)thiophen-2-yl)methanamine (2h). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (100 mg, 0.325 mmol), tetrahydroquinoline (44.9 μ L, 0.357 mmol), Et₃N (100 μ L, 0.715 mmol), and DCM (1.6 mL), 2 h, rt and (ii) 7 N NH₃ in MeOH (5 mL), rt, 20 h. The crude was purified by chromatography (1 N NH₃ in MeOH/DCM 0 → 10%) to afford a brown foam (27 mg, 27%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.78 (d, *J* = 8.3 Hz, 1H), 7.25–7.16 (m, 2H), 7.13–7.02 (m, 2H), 6.84 (d, *J* = 3.7 Hz, 1H), 4.04 (s, 2H), 3.87–3.81 (m, 2H), 2.54 (t, *J* = 6.7 Hz, 2H), 2.37–1.82 (m, 2H), 1.80–1.72 (br, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 137.52, 136.43, 132.42, 130.96, 129.27, 126.69, 125.28, 125.03, 123.78, 46.98, 41.34, 26.93, 21.78. HRMS (ESI) for C₁₄H₁₇N₂O₂S₂ ([M + H]⁺): calculated 309.0726; observed 309.0732; error = 1.9 ppm.

(5-(Morpholinomethyl)thiophen-2-yl)methanamine (2i).

The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (75 mg, 0.244 mmol), morpholine (42.7 μ L, 0.487 mmol), and DCM (1.2 mL), 16 h, rt and (ii) 1 M NaOH (1 mL) and MeOH (1 mL), rt, 16 h. The crude was dissolved in MeOH, passed through an SCX ion exchange (sulfonic acid) column, and washed with MeOH. The amine was released by the addition of 1 N NH₃ in MeOH to afford a crystalline solid (47 mg, 73%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.40 (d, *J* = 3.7 Hz, 1H), 6.95 (d, *J* = 3.6 Hz, 1H), 4.08 (br, 2H), 3.90–3.65 (m, 4H), 3.15–2.89 (m, 4H), 1.64 (br, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 133.16, 133.01, 123.70, 66.13, 46.12. HRMS (ESI) for C₉H₁₅N₂O₃S₂ ([M + H]⁺): calculated 263.0519; observed 263.0533; error = 5.3 ppm.

(5-(1,4-Diazepan-1-ylsulfonyl)thiophen-2-yl)methanamine Dihydrochloride (2j).

tert-Butyl 4-((5-(aminomethyl)thiophen-2-yl)sulfonyl)-1,4-diazepan-1-carboxylate was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (75 mg, 0.244 mmol), *N*-Boc-homopiperazine (53.7 mg, 0.268 mmol), Et₃N (74.7 μ L, 0.536 mmol), and DCM (1.2 mL), rt, 16 h and (ii) 1 M NaOH (5 mL), MeOH (5 mL), rt, 16 h. The crude was used in the subsequent transformation immediately.

Compound **2j** was synthesized according to general procedure GP2, from *tert*-butyl 4-((5-(aminomethyl)thiophen-2-yl)sulfonyl)-1,4-diazepan-1-carboxylate (crude) and 2 M HCl in Et₂O (10 mL), rt, 16. Compound **2j** was obtained as a pink solid (43 mg, 63%). ¹H NMR (500 MHz, D₂O) δ 7.77 (br, 1H), 7.44 (br, 1H), 4.55 (s, 2H), 3.75 (br, 2H), 3.60–3.45 (m, 6H), 2.23 (br, 2H). ¹³C NMR (126 MHz, D₂O) δ 141.90, 137.80, 133.32, 130.36, 47.20, 46.84, 44.85, 44.38, 37.31, 25.22. HRMS (ESI) for C₁₀H₁₈N₃O₂S₂ ([M + H]⁺): calculated 276.0835; observed 276.0771; error = 23 ppm.

(5-(4-Methyl-1,4-diazepan-1-ylsulfonyl)thiophen-2-yl)methanamine (2k).

A mixture of sulfonyl chloride **11a** (645 mg, 2.10 mmol), *N*-Boc-homopiperazine (449 μ L, 2.31 mmol), Et₃N (643 μ L, 4.61 mmol), and DCM (10 mL) was stirred at rt for 2 h. One molar HCl (30 mL) was added. The aqueous phase was extracted with DCM (3 \times 15 mL). The combined organic phase was dried over MgSO₄ and filtered, and the solvent was removed under reduced pressure. The intermediate was dissolved in 2 M HCl in Et₂O (10 mL), and the mixture was stirred at rt for 16 h. The solids were collected, washed with Et₂O, and dried under vacuum to afford *N*-((5-((1,4-diazepan-1-yl)sulfonyl)thiophen-2-yl)methyl)-2,2,2-trifluoroacetamide hydrochloride as a beige solid (580 mg, 68%). ¹H NMR (500 MHz, D₂O) δ 7.70 (m, 1H), 7.27 (m, 1H), 3.74–3.70 (m, 2H), 3.56–3.42 (m, 6H), 2.27–2.13 (m, 2H). HRMS (ESI) for C₁₂H₁₇F₃N₃O₂S₂ ([M + H]⁺): calculated 372.0658.

A mixture of *N*-((5-((1,4-diazepan-1-yl)sulfonyl)thiophen-2-yl)methyl)-2,2,2-trifluoroacetamide hydrochloride (80 mg, 0.196 mmol), MeI (18.0 μ L, 0.294 mmol), Et₃N (68.0 μ L, 0.490 mmol), and DCM (1.0 mL) was stirred at rt for 48 h. H₂O (10 mL) was added. The aqueous phase was extracted with DCM (3 \times 10 mL). The combined organic phase was removed under reduced pressure. The intermediate was dissolved in 7 N NH₃ in MeOH (3 mL), and the mixture was stirred at rt for 24 h. The solvent was removed under reduced pressure, and the crude was purified by chromatography (1 N NH₃ in MeOH/DCM 0 → 20%) to afford compound **2k** as a brown oil (12 mg, 21%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.40 (d, *J* = 3.7 Hz, 1H), 6.89 (dt, *J* = 3.7, 0.9 Hz, 1H), 4.10 (d, *J* = 0.8 Hz, 2H), 3.45–3.38 (m, 4H), 2.69–2.61 (m, 4H), 2.36 (s, 2H), 1.88 (dt, *J* = 11.7, 6.2 Hz, 2H), 1.69 (s, 3H). ¹³C NMR (126 MHz, chloroform-*d*) δ 155.05, 137.16, 131.90, 123.37, 58.55, 56.84, 48.04, 47.38, 46.58, 41.66, 27.55. HRMS (ESI) for C₁₁H₂₀N₃O₂S₂ ([M + H]⁺): calculated 290.0992; observed 290.0861; error = 45 ppm.

4-(5-(Aminomethyl)thiophen-2-ylsulfonyl)-*N*-ethyl-1,4-diazepan-1-carboxamide (2l). A mixture of *N*-((5-((1,4-diazepan-1-yl)sulfonyl)thiophen-2-yl)methyl)-2,2,2-trifluoroacetamide hydrochloride (80 mg, 0.196 mmol), EtNCO (17.0 μ L, 0.216 mmol), Et₃N (54.7 μ L, 0.392 mmol), and DCM (1.0 mL) was stirred at rt for 2 h. DCM (10 mL) was added. The organic phase was washed with H₂O and brine (10 mL each), dried over MgSO₄, and filtered, and the

solvent was removed under reduced pressure. The intermediate was dissolved in 7 N NH₃ in MeOH (3 mL), and the mixture was stirred at rt for 16 h. The solvent was removed under reduced pressure, and the crude was purified by chromatography (MeOH/DCM 0 → 20%) to afford compound **2l** as a colorless oil (60 mg, 88%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.38 (d, *J* = 3.7 Hz, 1H), 6.88 (dt, *J* = 3.7, 0.9 Hz, 1H), 4.39 (s, 1H), 4.08 (s, 2H), 3.62–3.57 (m, 2H), 3.49 (t, *J* = 6.4 Hz, 2H), 3.36–3.32 (m, 2H), 3.29–3.20 (m, 4H), 2.02–1.94 (m, 2H), 1.69 (s, 2H), 1.11 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (126 MHz, chloroform-*d*) δ 157.38, 155.48, 136.96, 132.01, 123.40, 50.69, 48.51, 48.13, 45.28, 41.58, 35.79, 28.24, 15.70. HRMS (ESI) for C₁₃H₂₃N₄O₃S₂ ([M + H]⁺): calculated 347.1206; observed 347.1196; error = 2.9 ppm.

(5-(4-(Methylsulfonyl)-1,4-diazepan-1-ylsulfonyl)thiophen-2-yl)methanamine (2m). A mixture of *N*-((5-((1,4-diazepan-1-yl)sulfonyl)thiophen-2-yl)methyl)-2,2,2-trifluoroacetamide hydrochloride (80 mg, 0.196 mmol), MsCl (16.7 μL, 0.216 mmol), Et₃N (68.0 μL, 0.490 mmol), and DCM (1.0 mL) was stirred at rt for 48 h. H₂O (10 mL) was added. The aqueous phase was extracted with DCM (3 × 10 mL). The combined organic phase was dried over MgSO₄ and filtered, and the solvent was removed under reduced pressure. The intermediate was dissolved in 7 N NH₃ in MeOH (3 mL), and the mixture was stirred at rt for 24 h. The solvent was removed under reduced pressure, and the crude was purified by chromatography (1 N NH₃ in MeOH/DCM 0 → 20%) to afford compound **2m** as a white solid (44 mg, 63%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.39 (d, *J* = 3.8 Hz, 1H), 6.88 (dt, *J* = 3.7, 1.0 Hz, 1H), 4.08 (d, *J* = 0.9 Hz, 2H), 3.54–3.34 (m, 8H), 2.85 (s, 3H), 2.00 (pentet, *J* = 6.3 Hz, 2H), 1.62 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 155.81, 136.76, 132.10, 123.37, 51.25, 50.49, 47.76, 47.27, 41.56, 38.13, 29.33. HRMS (ESI) for C₁₁H₂₀N₃O₄S₃ ([M + H]⁺): calculated 354.0611; observed 354.0530; error = 23 ppm.

(5-(Cyclohexylsulfonyl)thiophen-2-yl)methanamine (3a). NaH (60% in mineral oil; 39.6 mg, 0.985 mmol) was added to a solution of 5-bromothiophene-2-carbonitrile **17a** (100 μL, 0.901 mmol) and cyclohexylmercaptan (121 μL, 0.991 mmol) in DMF (3.0 mL), and the mixture was stirred at 130 °C for 16 h. After cooling to rt, EtOAc (15 mL) was added. The organic phase was washed with 1:1 H₂O/brine (3 × 15 mL), dried over MgSO₄, and filtered. The solvent was removed under reduced pressure, and the intermediate was dissolved in DCM (3.0 mL). mCPBA (77%; 489 mg, 2.18 mmol) was added in small portions, and the mixture was stirred at rt for 3 h. DCM (15 mL) was added. The organic phase was washed with 1 M NaOH (3 × 15 mL) and brine (15 mL), dried over MgSO₄, and filtered. The solvent was removed under reduced pressure, and the crude was purified by chromatography (EtOAc/cyclohexane 0 → 20%) to afford 5-(cyclohexylsulfonyl)thiophene-2-carbonitrile as a white crystalline solid (50 mg, 22%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.65 (d, *J* = 4.0 Hz, 1H), 7.61 (d, *J* = 4.0 Hz, 1H), 3.03 (tt, *J* = 12.1, 3.4 Hz, 1H), 2.19–2.11 (m, 2H), 1.97–1.88 (m, 2H), 1.72 (m, 1H), 1.65–1.10 (m, 5H). LCMS (ESI) *m/z* 278 [M + Na]⁺.

Compound **3a** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 0.58 mL, 0.58 mmol), 5-(cyclohexylsulfonyl)thiophene-2-carbonitrile (49 mg, 0.192 mmol), and THF (1.9 mL), rt, 1 h. The crude was purified by chromatography (MeOH/DCM 0 → 15%) to afford a white solid (12 mg, 24%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.50 (d, *J* = 3.8 Hz, 1H), 6.96 (m, 1H), 4.12 (s, 2H), 2.95 (tt, *J* = 12.1, 3.4 Hz, 1H), 2.20–2.12 (m, 2H), 1.92–1.84 (m, 2H), 1.68 (d, *J* = 21.7 Hz, 3H), 1.51–1.38 (m, 2H), 1.33–1.08 (m, 3H). ¹³C NMR (126 MHz, chloroform-*d*) δ 158.07, 135.80, 135.11, 123.83, 64.77, 41.72, 25.97, 25.27, 25.19. HRMS (ESI) for C₁₁H₁₇N₂O₂S₂ ([M + H]⁺): calculated 260.0773; observed 260.0785; error = 4.6 ppm.

(5-(Phenylsulfonyl)thiophen-2-yl)methanamine (3b). A mixture of nitrile **6c** (39 mg, 0.156 mmol), LiAlH₄ (1.0 M in THF; 160 μL, 0.160 mmol), and THF (1.6 mL) was stirred at 0 °C for 1 h. H₂O (5 mL) was slowly added, and the aqueous phase was extracted with DCM (3 × 8 mL). The combined organic phase was washed with brine (10 mL), dried over MgSO₄, and filtered. The solvent was

removed under reduced pressure, and the crude was purified by chromatography (7 N NH₃ in MeOH/DCM 0 → 60%) to afford compound **3b** as a light brown crystalline solid (15 mg, 38%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.01–7.95 (m, 2H), 7.63–7.48 (m, 4H), 6.88 (dt, *J* = 3.8, 1.0 Hz, 1H), 4.07 (s, 2H), 1.58 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 158.19, 142.50, 140.63, 133.70, 133.26, 129.39, 127.41, 123.80, 41.71. HRMS (ESI) for C₁₁H₁₂N₂O₂S₂ ([M + H]⁺): calculated 254.0304; observed 254.0309; error = 2.0 ppm.

(5-(Pyridin-2-ylsulfonyl)thiophen-2-yl)methanamine (3c). A mixture of 2-((5-methylthiophen-2-yl)sulfonyl)pyridine **15** (310 mg, 1.30 mmol), Bz₂O₂ (75%; 20.9 mg, 0.0648 mmol), NBS (253 mg, 1.42 mmol), and DCE (6.5 mL) was stirred at 80 °C for 16 h. The solvent was removed under reduced pressure, and the crude was purified by chromatography (EtOAc/cyclohexane 20 → 40%) to afford 2-((5-(bromomethyl)thiophen-2-yl)sulfonyl)pyridine as a white solid (294 mg, 71%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.74 (s, 1H), 8.19 (s, 1H), 7.97 (s, 1H), 7.71 (s, 1H), 7.53 (s, 1H), 7.13 (d, *J* = 3.9 Hz, 1H), 4.66 (s, 2H). LCMS (ESI) *m/z* 318/320 [M + H]⁺.

A mixture of 2-((5-(bromomethyl)thiophen-2-yl)sulfonyl)pyridine (133 mg, 0.418 mmol), NaN₃ (32.6 mg, 0.502 mmol), and DMF (2.1 mL) was stirred at 70 °C for 16 h. After cooling to rt, EtOAc (20 mL) was added. The organic phase was washed with 1:1 H₂O/brine (2 × 20 mL), dried over MgSO₄, and filtered. The solvent was removed under reduced pressure, and the intermediate was dissolved in THF (2.1 mL), and Pd/C (10%; 44 mg, 0.0418 mmol) was then added. The mixture was stirred at rt under a H₂ atmosphere (balloon) for 16 h and subsequently filtered through celite. The solvent was removed under reduced pressure, and the crude was purified by chromatography (MeOH/DCM 0 → 20%) to afford compound **3c** as a white solid (53 mg, 50%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.69 (ddd, *J* = 4.7, 1.7, 0.9 Hz, 1H), 8.15 (dt, *J* = 7.9, 1.0 Hz, 1H), 7.92 (td, *J* = 7.8, 1.7 Hz, 1H), 7.70 (d, *J* = 3.8 Hz, 1H), 7.46 (ddd, *J* = 7.6, 4.7, 1.1 Hz, 1H), 6.92 (dt, *J* = 3.9, 1.0 Hz, 1H), 4.07 (d, *J* = 0.9 Hz, 2H), 1.62 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 159.60, 159.12, 150.48, 138.27, 136.95, 135.65, 127.01, 123.94, 121.78, 41.71. HRMS (ESI) for C₁₀H₁₁N₂O₂S₂ ([M + H]⁺): calculated 255.0257; observed 255.0276; error = 7.5 ppm.

(5-(Thiophen-2-ylsulfonyl)thiophen-2-yl)methanamine Hydrochloride (3d). The titled compound was synthesized according to general procedures GP4, GP5, and GP3, from (i) 5-bromothiophene-2-carbonitrile **17a** (1.0 g, 5.32 mmol), thiophene-2-thiol (586 mg, 5.05 mmol), K₂CO₃ (881 mg, 6.38 mmol), and DMF (17 mL), 80 °C, 16 h; (ii) mCPBA (77%; 1.30 g, 11.2 mmol) and DCM (36 mL), rt, 3 h; and (iii) BH₃ (1.0 M in THF; 10.6 mL, 10.6 mmol) and THF (10.6 mL), rt, 1 h. Chromatography (EtOH/cyclohexane 0 → 100%) afforded a brown gum (323 mg, 25%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.64 (dd, *J* = 5.0, 1.3 Hz, 1H), 7.52 (dd, *J* = 3.7, 1.3 Hz, 1H), 7.43 (d, *J* = 3.7 Hz, 1H), 7.11 (dd, *J* = 5.0, 3.7 Hz, 1H), 6.90 (dt, *J* = 3.7, 0.9 Hz, 1H), 3.93 (s, 2H), 1.63 (br, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 155.85, 147.91, 145.56, 131.64, 130.91, 129.86, 127.48, 123.47, 41.84. HRMS (ESI) for C₉H₇O₂S₃ ([M – NH₂]⁺): calculated 242.9608; observed 242.9608; error = 0 ppm.

(5-(Biphenyl-3-ylsulfonyl)thiophen-2-yl)methanamine Hydrochloride (3e). 5-([1,1'-biphenyl]-3-ylthio)thiophene-2-carbonitrile was synthesized according to general procedures GP4, from 5-bromothiophene-2-carbonitrile **17a** (160 mg, 1.11 mmol), [1,1'-biphenyl]-3-thiol (223 mg, 1.22 mmol), K₂CO₃ (308 mg, 2.23 mmol), and DMF (4.6 mL), 120 °C, 16 h. Chromatography (EtOAc/cyclohexane 0 → 20%) afforded a brown oil (327 mg, 92%). ¹H NMR (500 MHz, methanol-*d*₄) δ 7.13–7.80 (m, 11H). LCMS (ESI) *m/z* 294 [M + H]⁺.

tert-Butyl ((5-([1,1'-biphenyl]-3-ylthio)thiophen-2-yl)methyl)-carbamate was synthesized according to general procedures GP3 and GP6, from (i) 5-([1,1'-biphenyl]-3-ylthio)thiophene-2-carbonitrile (264 mg, 0.910 mmol), BH₃ (1.0 M in THF; 2.7 mL, 2.70 mmol), THF (2.7 mL), rt, 1 h and (ii) Boc₂O (590 mg, 2.70 mmol), Et₃N (250 μL, 1.80 mmol), and DCM (3.5 mL), rt, 16 h.

Chromatography (EtOAc/cyclohexane 0 → 30%) afforded a yellow oil (64 mg, 18%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.56 (m, 1H), 7.55 (m, 1H), 7.49 (m, 1H), 7.46 (m, 2H), 7.43–7.33 (m, 3H), 7.20 (m, 2H), 6.93 (d, *J* = 3.3 Hz, 1H), 5.04 (s, 1H), 4.49 (s, 2H), 1.50 (s, 9H). LCMS (ESI) *m/z* 281 [*M* – BocNH]⁺.

Compound **3e** was synthesized according to general procedures GP5 and GP2, from (i) *tert*-butyl ((5-([1,1'-biphenyl]-3-ylthio)thiophen-2-yl)methyl)carbamate (64 mg, 0.161 mmol), mCPBA (77%; 69 mg, 0.402 mmol), and DCM (2.0 mL), 45 °C, 1.5 h and (ii) 4 M HCl in dioxane (8.0 mL), rt, 16 h. The white precipitate was filtered and washed with excess EtOAc to afford a white solid (25 mg, 42% over two steps). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.19 (m, 1H), 7.99 (ddd, *J* = 7.8, 1.8, 1.0 Hz, 1H), 7.96 (ddd, *J* = 7.8, 1.8, 1.0 Hz, 1H), 7.81 (d, *J* = 3.9 Hz, 1H), 7.70 (t, *J* = 7.7 Hz, 1H), 7.65 (m, 2H), 7.52 (m, 2H), 7.44 (m, 1H), 7.32 (d, *J* = 3.8 Hz, 1H), 4.38 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 144.2, 143.8, 142.8, 142.4, 138.8, 133.8, 131.9, 130.3, 130.1, 128.9, 128.2, 126.7, 125.7, 125.1, 37.1. HRMS (ESI) for C₁₇H₁₃O₂S₂ ([*M* – NH₂]⁺): calculated 313.0357; observed 313.0359; error = 0.64 ppm.

(5-(Naphthalen-1-ylsulfonyl)thiophen-2-yl)methanamine (3f). 5-(Naphthalen-1-ylsulfonyl)thiophene-2-carbonitrile was synthesized according to general procedures GP4 and GP5, from (i) 5-chlorothiophene-2-carbonitrile **17a** (95 μL, 0.901 mmol), naphthalene-1-thiol (137 μL, 0.991 mmol), K₂CO₃ (250 mg, 1.80 mmol), and DMF (3.0 mL), 120 °C, 16 h and (ii) mCPBA (77%; 504 mg, 2.25 mmol) and DCM (15 mL), rt, 16 h. Chromatography (EtOAc/cyclohexane 0 → 15%) afforded a colorless oil (170 mg, 63%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.78 (m, 1H), 8.51 (dd, *J* = 7.4, 1.2 Hz, 1H), 8.17 (d, *J* = 8.2 Hz, 1H), 7.96 (d, *J* = 8.2 Hz, 1H), 7.75–7.67 (m, 2H), 7.67–7.59 (m, 2H), 7.49 (d, *J* = 4.1 Hz, 1H). LCMS (ESI) *m/z* 300 [*M* + H]⁺.

Compound **3f** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 1.10 mL, 1.10 mmol), 5-(naphthalen-1-ylsulfonyl)thiophene-2-carbonitrile (110 mg, 0.367 mmol), and THF (1.8 mL), rt, 2 h. Chromatography (MeOH/DCM 0 → 20%) afforded a white crystalline solid (25 mg, 23%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.86 (dd, *J* = 8.7, 0.8 Hz, 1H), 8.47 (dd, *J* = 7.4, 1.2 Hz, 1H), 8.09 (d, *J* = 8.2 Hz, 1H), 7.95–7.87 (m, 1H), 7.70–7.64 (m, 2H), 7.63–7.54 (m, 2H), 6.84 (dt, *J* = 3.9, 1.0 Hz, 1H), 4.01 (d, *J* = 0.9 Hz, 2H), 1.58 (s, 3H). ¹³C NMR (126 MHz, chloroform-*d*) δ 157.61, 141.08, 137.18, 135.25, 134.40, 133.68, 129.61, 129.23, 128.54, 127.07, 124.65, 124.63, 123.50, 41.67. HRMS (ESI) for C₁₅H₁₁O₂S₂ ([*M* – NH₂]⁺): calculated 287.0195; observed 287.0226; error = 11 ppm.

(5-(Naphthalen-2-ylsulfonyl)thiophen-2-yl)methanamine (3g). Compound **3g** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 5.10 mL, 5.10 mmol), 5-(naphthalen-2-ylsulfonyl)thiophene-2-carbonitrile **43** (510 mg, 1.71 mmol) and THF (10 mL), rt, 3 h. Chromatography (EtOH/cyclohexane 30 → 100%) afforded a white solid (273 mg, 54%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.58 (s, 1H), 8.01–7.87 (m, 4H), 7.68–7.57 (m, 3H), 6.88 (m, 1H), 4.05 (s, 2H), 1.56 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 158.24, 140.73, 139.30, 135.17, 133.73, 132.40, 129.75, 129.59, 129.25, 128.71, 128.06, 127.75, 123.82, 122.58, 41.68. HRMS (ESI) for C₁₅H₁₁O₂S₂ ([*M* – NH₂]⁺): calculated 287.0195; observed 287.0207; error = 4.2 ppm.

N-(4-(5-(Aminomethyl)thiophen-2-ylsulfonyl)phenyl)methanesulfonamide (3h). A mixture of 5-((4-aminophenyl)thio)thiophene-2-carbonitrile **19** (120 mg, 0.517 mmol), MsCl (44.0 μL, 0.568 mmol), and pyridine (1.7 mL) was stirred at rt for 16 h. Two molar HCl (30 mL) was added. The aqueous phase was extracted with DCM (3 × 20 mL). The combined organic phase was dried over MgSO₄ and filtered. The solvent was removed under reduced pressure, and the crude was dissolved in DCM (2.6 mL). mCPBA (77%; 254 mg, 1.14 mmol) was added, and the mixture was stirred at rt for 5 h. sat. NaHCO₃ (40 mL) was added, and the aqueous phase was extracted with EtOAc (3 × 40 mL). The combined organic phase was dried over MgSO₄ and filtered. The solvent was removed under reduced pressure, and the crude was purified by chromatography (MeOH/DCM 0 → 15%) to afford *N*-(4-((5-cyanothiophen-2-

yl)sulfonyl)phenyl)methanesulfonamide as a white solid (69 mg, 39%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.50 (d, *J* = 3.9 Hz, 1H), 7.41–7.37 (m, 2H), 7.26–7.19 (m, 3H), 7.09 (d, *J* = 3.9 Hz, 1H), 3.05 (s, 3H). LCMS (ESI) *m/z* 365 [*M* + Na]⁺.

Compound **3h** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 0.61 mL, 0.61 mmol), *N*-(4-((5-cyanothiophen-2-yl)sulfonyl)phenyl)methanesulfonamide (69 mg, 0.202 mmol), and THF (0.6 mL), rt, 1 h. Chromatography (MeOH/DCM 5 → 25%) afforded a yellow solid (2 mg, 3%). ¹H NMR (500 MHz, methanol-*d*₄) δ 7.90–7.84 (m, 2H), 7.58 (d, *J* = 3.8 Hz, 1H), 7.38–7.32 (m, 2H), 7.04 (d, *J* = 3.8 Hz, 1H), 4.02 (s, 2H), 3.03 (s, 3H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 156.79, 146.06, 142.74, 136.92, 134.52, 130.00, 126.62, 119.69, 41.34, 40.06. HRMS (ESI) for C₁₂H₁₃N₂O₄S₂ ([*M* + H]⁺): calculated 347.0189; observed 347.0190; error = 0.29 ppm.

(5-(4-(Methylsulfonyl)phenylsulfonyl)thiophen-2-yl)methanamine (3i). 5-((4-(Methylsulfonyl)phenyl)sulfonyl)thiophene-2-carbonitrile was synthesized according to general procedures GP4 and GP5, from (i) 5-chlorothiophene-2-carbonitrile (500 mg, 3.48 mmol), 4-(methylthio)benzenethiol (599 mg, 3.83 mmol), K₂CO₃ (960 mg, 7.00 mmol), and DMF (11.6 mL), 120 °C, 16 h and (ii) mCPBA (77%; 3.90 g, 17.4 mmol) and DCM (23 mL), rt, 2 h. A white solid was obtained, which did not require further purification (770 mg, 68%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.35–8.29 (m, 2H), 8.24–8.18 (m, 2H), 8.13–8.08 (m, 2H), 3.31 (s, 3H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 147.29, 145.83, 144.19, 140.29, 134.79, 128.78, 128.56, 116.87, 112.57, 42.92.

Compound **3i** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 8.40 mL, 8.40 mmol), 5-((4-(methylsulfonyl)phenyl)sulfonyl)thiophene-2-carbonitrile (921 mg, 2.81 mmol), and THF (18 mL), 50 °C, 3 h. Chromatography (MeOH/DCM 0 → 20%) afforded a white solid (310 mg, 34%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.19–8.15 (m, 2H), 8.11–8.06 (m, 2H), 7.63 (d, *J* = 3.9 Hz, 1H), 6.93 (dt, *J* = 3.8, 1.0 Hz, 1H), 4.09 (d, *J* = 0.8 Hz, 2H), 3.08 (s, 3H), 1.61 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 160.12, 147.61, 144.80, 138.67, 134.95, 128.64, 128.46, 124.12, 44.41, 41.70. HRMS (ESI) for C₁₂H₁₄NO₄S₂ ([*M* + H]⁺): calculated 332.0080; observed 332.0070; error = 3.0 ppm.

(5-(4-(Methylsulfonyl)butylsulfonyl)thiophen-2-yl)methanamine (3j). A mixture of 2-methyl-5-((4-(methylsulfonyl)butyl)sulfonyl)thiophene **16** (860 mg, 2.90 mmol), Bz₂O₂ (75%; 46.8 mg, 0.145 mmol), NBS (568 mg, 3.19 mmol), and DCE (14.5 mL) was stirred at 70 °C for 16 h. The solvent was removed under reduced pressure, and the crude was dissolved in DMF (14.5 mL). NaN₃ (226 mg, 3.40 mmol) was added and the mixture was stirred at 70 °C for 5 h. After cooling to rt, EtOAc (30 mL) was added. The organic phase was washed with 1:1 H₂O/brine (3 × 30 mL), dried over MgSO₄, and filtered. The solvent was removed under reduced pressure, and the crude was purified by chromatography (EtOAc/DCM 5 → 30%) to afford 2-(azidomethyl)-5-((4-(methylsulfonyl)butyl)sulfonyl)thiophene as a colorless oil (414 mg, 42%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.61 (d, *J* = 3.9 Hz, 1H), 7.09 (m, 1H), 4.59 (s, 2H), 3.33–3.22 (m, 2H), 3.13–3.01 (m, 2H), 2.92 (s, 3H), 2.13–1.92 (m, 4H). LCMS (ESI) *m/z* 360 [*M* + Na]⁺.

A mixture of (azidomethyl)-5-((4-(methylsulfonyl)butyl)sulfonyl)thiophene (410 mg, 1.22 mmol) and Pd/C (10%; 129 mg, 0.122 mmol) in THF (6.1 mL) was stirred at rt under H₂ atmosphere (balloon) for 16 h and subsequently filtered through celite. The solvent was removed under reduced pressure, and the crude was purified by chromatography (MeOH/DCM 0 → 20%) to afford compound **3j** as a white solid (27 mg, 6%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.54 (d, *J* = 3.8 Hz, 1H), 6.95 (m, 1H), 4.11 (s, 2H), 3.25–3.19 (m, 2H), 3.05–3.00 (m, 2H), 2.89 (s, 3H), 2.03–1.91 (m, 4H), 1.71 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 158.73, 137.14, 134.65, 123.97, 56.81, 53.92, 41.63, 40.85, 22.16, 21.11. HRMS (ESI) for C₁₀H₁₈NO₄S₂ ([*M* + H]⁺): calculated 312.0393; observed 312.0417; error = 7.7 ppm.

(5-(Phenylsulfonyl)thiophen-2-yl)methanamine (4a). 5-(Phenylsulfonyl)thiophene-2-carbonitrile was synthesized according to general procedures GP5, from mCPBA (77%; 143 mg, 0.636

mmol) and 5-(phenylthio)thiophene-2-carbonitrile **29** (138 mg, 0.636 mmol) in DCM (3 mL), rt, 16 h. Chromatography (EtOAc/cyclohexane 0 → 20%) afforded a colorless oil (127 mg, 86%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.76–7.70 (m, 2H), 7.60–7.50 (m, 4H), 7.44 (d, *J* = 4.0 Hz, 1H). LCMS (ESI) *m/z* 233 [*M* + *H*]⁺.

Compound **4a** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 1.70 mL, 1.70 mmol), 5-(naphthalen-2-ylsulfonyl)thiophene-2-carbonitrile (132 mg, 0.568 mmol), and THF (2.8 mL), rt, 2 h. Chromatography (MeOH/DCM 0 → 20%) afforded a yellow oil (53 mg, 40%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.72–7.65 (m, 2H), 7.54–7.43 (m, 4H), 6.86 (m, 1H), 4.00 (s, 2H), 1.80 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 156.03, 145.85, 145.18, 132.03, 131.13, 129.26, 124.42, 123.46, 41.74. HRMS (ESI) for C₁₁H₁₂NOS₂ ([*M* + *H*]⁺): calculated 238.0355; observed 238.0378; error = 9.7 ppm.

(5-(Phenylthio)thiophen-2-yl)methanamine Hydrochloride (4b). The titled compound was synthesized according to general procedure GP2, from 4 M HCl in dioxane (2.5 mL) and *tert*-butyl ((5-(phenylthio)thiophen-2-yl)methyl)carbamate (60.1 mg, 0.189 mmol), rt, 3 h. A white solid was obtained, which did not require further purification (29 mg, 60%). ¹H NMR (500 MHz, methanol-*d*₄) δ 7.36–7.14 (m, 7H), 4.32 (s, 2H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 141.06, 138.75, 136.99, 135.89, 131.40, 130.24, 129.20, 127.91, 38.79. HRMS (ESI) for C₁₁H₉S₂ ([*M* – NH₂]⁺): calculated 205.0146; observed 205.1050; error = 2.0 ppm.

5-(Aminomethyl)-*N*-benzylthiophene-2-sulfonamide (4c). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11a** (100 mg, 0.325 mmol), benzylamine (88.7 μL, 0.812 mmol), and DCM (1.63 mL), 16 h, rt and (ii) 30% NaOH (0.5 mL) and MeOH (3 mL), rt, 16 h. A colorless oil (59 mg, 64%) was obtained, which did not require further purification. ¹H NMR (500 MHz, chloroform-*d*) δ 7.44 (d, *J* = 3.7 Hz, 1H), 7.32–7.20 (m, 5H), 6.84 (d, *J* = 3.6 Hz, 1H), 5.24 (br, 1H), 4.19 (s, 2H), 4.02 (s, 2H), 1.87 (br, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 132.60, 128.77, 128.02, 127.98, 123.55, 47.50, 41.43. HRMS (ESI) for C₁₂H₁₅N₂O₂S₂ ([*M* + *H*]⁺): calculated 283.0570; observed 283.0573; error = 1.1 ppm.

5-(Aminomethyl)-*N*-benzylthiophene-2-carboxamide (4d). A mixture of methyl 5-(azidomethyl)thiophene-2-carboxylate **44** (A = S) (1.77 g, 8.98 mmol), 1 M NaOH (30 mL), and MeOH (30 mL) was stirred at rt for 16 h. The pH was subsequently adjusted to <2 with 2 M HCl. The aqueous phase was extracted with DCM (3 × 30 mL). The combined organic phase was dried over MgSO₄ and filtered, and the solvent was removed under reduced pressure. The crude was dissolved in DCM (21.8 mL), and oxalyl chloride (0.61 mL, 7.20 mmol) was added, followed by DMF (two drops). The mixture was stirred at rt for 3 h, and the solvent was removed under reduced pressure to afford acyl chloride **45** (A = S) as an orange oil (1.25 g, 75%). Acyl chloride **45** was used in the subsequent transformation without further purification.

Benzylamine (120 μL, 1.09 mmol) was added to a solution of acyl chloride **45** (100 mg, 0.496 mmol) and DCM (2.5 mL), and the mixture was stirred at rt for 3 h. Two molar HCl (10 mL) was added, and the aqueous phase was extracted with DCM (3 × 10 mL). The combined organic phase was dried over MgSO₄, filtered, and the solvent was removed under reduced pressure. The crude was dissolved in THF (2.5 mL), and 10% Pd/C (53 mg) was added. The mixture was stirred under a H₂ atmosphere (balloon) at rt for 24 h and was subsequently filtered through celite. The solvent was removed under reduced pressure, and the crude was purified by chromatography (1 N NH₃ in MeOH/DCM 0 → 20%) to afford compound **4d** as a white solid (55 mg, 45%). ¹H NMR (500 MHz, methanol-*d*₄) δ 7.36–7.19 (m, 5H), 7.04 (d, *J* = 3.4 Hz, 1H), 6.37 (d, *J* = 3.3 Hz, 1H), 4.52 (s, 2H), 3.81 (s, 2H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 160.84, 159.70, 147.96, 140.02, 129.53, 128.59, 128.25, 116.26, 109.12, 43.74, 39.37. HRMS (ESI) for C₁₃H₁₅N₂OS ([*M* + *H*]⁺): calculated 247.0905; observed 247.0907; error = 0.81 ppm.

(5-(4-(Methylsulfonyl)phenyl)thiophen-2-yl)methanamine Hydrochloride (4e). The titled compound was synthesized

according to general procedures GP2, from *tert*-butyl ((5-(4-(methylsulfonyl)phenyl)thiophen-2-yl)methyl)carbamate **59** (267 mg, 0.797 mmol), 4 M HCl in dioxane (4 mL), and DCM (4 mL), rt, 16 h. A light yellow solid was obtained that did not require further purification (138 mg, 64%). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.01–7.96 (m, 2H), 7.93–7.89 (m, 2H), 7.57 (d, *J* = 3.7 Hz, 1H), 7.29 (d, *J* = 3.8 Hz, 1H), 4.36 (s, 2H), 3.16 (s, 3H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 144.98, 140.90, 140.20, 137.74, 131.83, 129.37, 127.31, 126.97, 44.36, 38.86. HRMS (ESI) for C₁₂H₁₁O₂S₂ ([*M* – NH₂]⁺): calculated 251.0200; observed 251.0196; error = 1.6 ppm.

(6-(Benzylsulfonyl)pyridin-3-yl)methanamine Dihydrochloride (5a). The titled compound was synthesized according to general procedures GP5 and GP2, from (i) sulfide **47** (44 mg, 0.133 mmol), mCPBA (50%; 115 mg, 0.333 mmol), and DCM (0.6 mL) at rt for 16 h and (ii) 2 M HCl in Et₂O (2.0 mL), DCM (1.0 mL), rt, 20 h. Chromatography (1 N NH₃ in MeOH/DCM 0 → 20%) afforded a white solid (27 mg, 77%). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.76 (m, 1H), 7.92 (m, 1H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.30–7.16 (m, 5H), 4.68 (s, 2H), 3.92 (s, 2H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 155.78, 150.77, 144.38, 138.22, 132.22, 129.66, 129.53, 129.19, 129.14, 124.10, 59.32, 43.72. HRMS (ESI) for C₁₃H₁₅N₂O₂S₂ ([*M* + *H*]⁺): calculated 263.0849; observed 263.0848; error = 0.38 ppm.

(5-(Benzylsulfonyl)thiophen-2-yl)methanamine (5b). 5-(Benzylsulfonyl)thiophene-2-carbonitrile was synthesized according to general procedures GP4 and GP5, from (i) 5-bromothiophene-2-carbonitrile **17a** (150 μL, 1.35 mmol), benzylmercaptan (174 μL, 1.49 mmol), NaH (60% in mineral oil; 59.5 mg, 1.49 mmol), and DMF (4.5 mL), 140 °C, 16 h and (ii) mCPBA (77%; 757 mg, 3.38 mmol) and DCM (4.5 mL), rt, 4 h. Chromatography (EtOAc/cyclohexane 0 → 20%) afforded a white solid (318 mg, 89%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.07 (d, *J* = 4.0 Hz, 1H), 7.72 (d, *J* = 4.0 Hz, 1H), 7.40–7.32 (m, 3H), 7.25–7.18 (m, 2H), 4.93 (s, 2H). LCMS (ESI) *m/z* 286 [*M* + Na]⁺.

Compound **5b** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 1.10 mL, 1.10 mmol), 5-(benzylsulfonyl)thiophene-2-carbonitrile (151 mg, 0.570 mmol), and THF (2.8 mL) at rt for 1 h. Chromatography (MeOH/DCM 0 → 20%) afforded a white crystalline solid (23 mg, 15%). ¹H NMR (500 MHz, chloroform-*d*) δ 7.38–7.26 (m, 3H), 7.21–7.15 (m, 3H), 6.84 (dt, *J* = 3.8, 1.0 Hz, 1H), 4.39 (s, 2H), 4.07 (d, *J* = 0.9 Hz, 2H), 1.59 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 158.50, 136.25, 135.25, 130.88, 129.00, 128.74, 128.52, 123.68, 64.15, 41.68. HRMS (ESI) for C₁₂H₁₄NO₂S₂ ([*M* + *H*]⁺): calculated 268.0462; observed 268.0462; error = 0.37 ppm.

(2-(Naphthalen-2-ylsulfonyl)thiazol-5-yl)methanamine hydrochloride (5c). *tert*-Butyl ((2-(naphthalen-2-ylthio)thiazol-5-yl)methyl)carbamate was synthesized according to general procedures GP4, GP3, and GP6, from (i) 2-chlorothiazole-5-carbonitrile **17b** (580 mg, 4 mmol), naphthalene-2-thiol (640 mg, 4 mmol), K₂CO₃ (800 mg, 5.8 mmol), and DMF (10 mL) at 60 °C for 24 h. Chromatography (DCM/cyclohexane 0 → 100%) 400 mg, 37%; (ii) 2-(naphthalen-2-ylthio)thiazole-5-carbonitrile (400 mg, 1.5 mmol), BH₃ (1.0 M in THF; 5 mL, 5 mmol), THF (20 mL) at rt for 18 h. Chromatography (EtOAc/DCM 0 → 100%) 120 mg, 26%; (iii) (2-(naphthalen-2-ylthio)thiazol-5-yl)methanamine (120 mg, 0.4 mmol), Boc₂O (109 mg, 0.5 mmol), Et₃N (70 μL, 0.5 mmol), THF (5 mL), rt, 18 h. Chromatography (EtOAc/DCM 0 → 50%) to afford *tert*-butyl ((2-(naphthalen-2-ylthio)thiazol-5-yl)methyl)carbamate (110 mg, 74%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.79 (d, *J* = 1.9 Hz, 1H), 8.29 (d, *J* = 8.2 Hz, 1H), 8.20 (d, *J* = 8.7 Hz, 1H), 8.09 (d, *J* = 8.1 Hz, 1H), 7.95 (dd, *J* = 8.6, 2.0 Hz, 1H), 7.91 (s, 1H), 7.82–7.75 (m, 1H), 7.72 (ddd, *J* = 8.0, 6.9, 1.3 Hz, 1H), 7.65 (t, *J* = 6.1 Hz, 1H), 4.36 (d, *J* = 6.0 Hz, 2H), 1.38 (s, 9H). LCMS (ESI) *m/z* 373 [*M* + *H*]⁺.

Compound **5c** was synthesized according to general procedures GP5 and GP2, from (i) *tert*-butyl ((2-(naphthalen-2-ylthio)thiazol-5-yl)methyl)carbamate (110 mg, 0.296 mmol), mCPBA (77%; 340 mg, 1.52 mmol), and DCM (5.0 mL) at rt for 3 h and (ii) 4 M HCl in dioxane (2.0 mL) and dioxane (5 mL), at rt, for 16 h. The white precipitate was filtered, washed with excess dioxane, and dried under

vacuum to afford the desired compound as a white solid (33 mg, 37%). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 8.82 (d, $J = 2.0$ Hz, 1H), 8.49 (s, 3H), 8.31 (d, $J = 8.2$ Hz, 1H), 8.23 (d, $J = 8.7$ Hz, 1H), 8.15 (s, 1H), 8.10 (d, $J = 8.1$ Hz, 1H), 7.97 (dd, $J = 8.6, 2.1$ Hz, 1H), 7.84–7.77 (m, 1H), 7.77–7.71 (m, 1H), 4.39 (s, 2H). HRMS (ESI) for $\text{C}_{14}\text{H}_{13}\text{N}_2\text{O}_2\text{S}_2$ [$\text{M} + \text{H}$] $^+$: calculated 305.0413; observed 305.0471; error = 19 ppm.

(5-(Naphthalen-2-ylsulfonyl)thiazol-2-yl)methanamine Hydrochloride (5d). The titled compound was synthesized according to general procedures GP5 and GP2, from (i) *tert*-butyl ((5-(naphthalen-2-ylthio)thiazol-2-yl)methyl)carbamate **49** (200 mg, 0.537 mmol), mCPBA (77%; 300 mg, 1.34 mmol), and DCM (4 mL) at rt for 18 h; chromatography (EtOAc/cyclohexane 0 \rightarrow 60%) and (ii) 4 M HCl in dioxane (1.6 mL) at rt for 4 h. The mixture was diluted with Et_2O and the precipitate collected using filtration, washed with excess Et_2O , and dried under vacuum to afford the compound as a white solid (106 mg, 52% over two steps). ^1H NMR ($\text{DMSO-}d_6$, 500 MHz) δ 8.79 (d, 1H, $J = 1.8$ Hz), 8.72 (br s, 3H), 8.65 (s, 1H), 8.27 (d, 1H, $J = 8.4$ Hz), 8.21 (d, 1H, $J = 8.8$ Hz), 8.09 (d, 1H, $J = 8.2$ Hz), 8.00 (dd, 1H, $J = 8.7, 2.0$ Hz), 7.78 (ddd, 1H, $J = 8.2, 6.9, 1.3$ Hz), 7.73 (ddd, 1H, $J = 8.1, 6.9, 1.3$ Hz), 4.46 (s, 2H); ^{13}C NMR ($\text{DMSO-}d_6$, 125 MHz) δ 170.3, 147.4, 140.2, 137.6, 134.9, 131.8, 130.4, 130.0, 129.7, 128.8, 128.2, 128.0, 121.8, 39.7; HRMS (ESI) for $\text{C}_{14}\text{H}_{13}\text{N}_2\text{O}_2\text{S}_2$ [$\text{M} + \text{H}$] $^+$: calculated 305.0402; observed 305.0413; error = 3.6 ppm.

5-(Aminomethyl)-*N*-benzylfuran-2-carboxamide (5e). Benzylamine (130 μL , 1.19 mmol) was added to a solution of acyl chloride **45** (A = O; 100 mg, 0.539 mmol) and DCM (2.7 mL), and the mixture was stirred at rt for 1 h. Two molar HCl (10 mL) was added, and the aqueous phase was extracted with DCM (3 \times 10 mL). The combined organic phase was dried over MgSO_4 and filtered, and the solvent was removed under reduced pressure. The crude was dissolved in THF (2.7 mL), and 10% Pd/C (57.3 mg) was added. The mixture was stirred under a H_2 atmosphere (balloon) at rt for 20 h and was subsequently filtered through celite. The solvent was removed under reduced pressure, and the crude was purified by chromatography (1 N NH_3 in MeOH/DCM 0 \rightarrow 20%) to afford compound **5e** as a light brown oil (48 mg, 39%). ^1H NMR (500 MHz, methanol- d_4) δ 7.56 (d, $J = 3.8$ Hz, 1H), 7.38–7.18 (m, 5H), 6.98 (d, $J = 3.8$ Hz, 1H), 4.51 (s, 2H), 3.96 (s, 2H). ^{13}C NMR (126 MHz, methanol- d_4) δ 164.43, 152.94, 140.21, 138.59, 129.85, 129.56, 128.56, 128.22, 126.28, 44.41, 41.61. HRMS (ESI) for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$: calculated 253.0953; observed 253.0960; error = 2.8 ppm.

(5-(Indolin-1-ylsulfonyl)-4-methylthiophen-2-yl)-methanamine (5f). The titled compound was synthesized according to general procedure GP1, from (i) sulfonyl chloride **11b** (crude), Et_3N (44.4 μL , 0.319 mmol), indoline (33 μL , 0.294 mmol), and DCM (1.2 mL), rt, 3 h; (ii) 7 N NH_3 in MeOH (5 mL), rt for 20 h. Chromatography (1 N NH_3 in MeOH/DCM 0 \rightarrow 10%) afforded a compound as a light brown foam (54 mg, 73%). ^1H NMR (500 MHz, chloroform- d) δ 7.59 (d, $J = 8.1$ Hz, 1H), 7.21–7.10 (m, 2H), 7.00 (td, $J = 7.4, 0.9$ Hz, 1H), 6.68 (s, 1H), 4.03 (t, $J = 8.4$ Hz, 2H), 3.96 (s, 2H), 2.97 (t, $J = 8.3$ Hz, 2H), 2.33 (s, 3H), 1.68–1.35 (br, 2H). ^{13}C NMR (126 MHz, chloroform- d) δ 153.13, 143.82, 141.96, 132.09, 129.42, 127.97, 127.69, 125.15, 124.08, 115.79, 50.22, 41.39, 28.16, 15.56. HRMS (ESI) for $\text{C}_{14}\text{H}_{17}\text{N}_2\text{O}_2\text{S}_2$ [$\text{M} + \text{H}$] $^+$: calculated 309.0726; observed 309.0726; error = 0 ppm.

***N*-Methyl-1-(5-(phenylsulfonyl)thiophen-2-yl)methanamine Hydrochloride (6a).** The titled compound was synthesized according to general procedure GP2, from *tert*-butyl methyl((5-(phenylsulfonyl)thiophen-2-yl)methyl)carbamate (57 mg, 0.155 mmol) and 4 M HCl in dioxane (2.5 mL) at rt for 16 h. Chromatography (EtOH/cyclohexane 50 \rightarrow 100%) afforded a white solid (43 mg, quant.). ^1H NMR (500 MHz, methanol- d_4) δ 8.01–7.93 (m, 2H), 7.67–7.55 (m, 4H), 7.05 (d, $J = 3.8$ Hz, 1H), 3.93 (s, 2H), 2.38 (s, 3H). ^{13}C NMR (126 MHz, methanol- d_4) δ 154.35, 143.60, 142.54, 134.90, 134.63, 130.61, 128.22, 127.79, 50.42, 35.41. HRMS (ESI) for $\text{C}_{12}\text{H}_{14}\text{NO}_2\text{S}_2$ [$\text{M} + \text{H}$] $^+$: calculated 268.0461; observed 268.0457; error = 1.5 ppm.

1-(5-(Phenylsulfonyl)thiophen-2-yl)ethanamine (6b). A mixture of sulfone **41** (177 mg, 0.665 mmol), hydroxylamine hydrochloride (76 mg, 1.10 mmol), and DIPEA (174 μL , 1.00 mmol) in EtOH (10 mL) was stirred at reflux for 18 h. After cooling to rt, the solvent was removed under reduced pressure. The crude was purified by chromatography (EtOAc/DCM 0 \rightarrow 100%) to afford 1-(5-(phenylsulfonyl)thiophen-2-yl)ethanone oxime (80 mg, 43%). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 11.72 (s, 1H), 8.01–7.95 (m, 2H), 7.79 (d, $J = 4.0$ Hz, 1H), 7.75–7.70 (m, 1H), 7.68–7.62 (m, 2H), 7.41 (d, $J = 4.0$ Hz, 1H), 2.14 (s, 3H).

A mixture of 1-(5-(phenylsulfonyl)thiophen-2-yl)ethanone oxime (80 mg, 0.142 mmol), Zn powder (\sim 10 mg), and TFA (4 mL) was stirred at rt for 1 h. The mixture was diluted with DCM and filtered through celite, and the solvent was removed under reduced pressure. EtOAc was added, and the solution was washed with sat. NaHCO_3 , dried over MgSO_4 , and filtered, and the solvent was removed under reduced pressure to afford compound **6b** (17 mg, 43%). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 7.96–7.92 (m, 2H), 7.70–7.67 (m, 2H), 7.65–7.61 (m, 2H), 7.01 (dd, $J = 3.9, 1.0$ Hz, 1H), 4.21 (qd, $J = 6.5, 1.0$ Hz, 1H), 2.40 (s, 2H), 1.30 (d, $J = 6.6$ Hz, 3H). LCMS (ESI) m/z 251 [$\text{M} - \text{NH}_2$] $^+$.

5-(Phenylsulfonyl)thiophene-2-carbonitrile (6c). The titled compound can be obtained in two steps from the method illustrated in Scheme 3 in the manuscript. An alternative one-step method is shown here: A mixture of 5-bromothiophene-2-carbonitrile **17a** (100 mg, 0.532 mmol), sodium benzenesulfinate (138 mg, 0.691 mmol), and DMF (1.0 mL) was stirred at 135 $^\circ\text{C}$ for 16 h. After cooling to rt, EtOAc (10 mL) was added. The organic phase was washed with H_2O (2 \times 10 mL) and brine (10 mL), dried over MgSO_4 , and filtered. The solvent was removed under reduced pressure, and the crude was purified by chromatography (EtOAc/cyclohexane 0 \rightarrow 20%) to afford nitrile **6c** as a white crystalline solid (67 mg, 51%). ^1H NMR (500 MHz, chloroform- d) δ 8.03–7.98 (m, 2H), 7.70–7.53 (m, 5H). ^{13}C NMR (126 MHz, chloroform- d) δ 150.24, 140.54, 137.42, 134.47, 132.39, 129.89, 127.86, 117.10, 112.37. HRMS (ESI) for $\text{C}_{11}\text{H}_7\text{NO}_2\text{S}_2$ [$\text{M} + \text{H}$] $^+$: calculated 249.9996; observed 250.0001; error = 2.0 ppm.

5-(Phenylsulfonyl)thiophene-2-carboximidamide Hydrochloride (6d). LiHMDS (225 mg, 1.35 mmol) was added to a mixture of nitrile **6c** (224 mg, 0.900 mmol) in Et_2O (10 mL), and the mixture was stirred at rt for 1 h. Two molar HCl (5 mL) was added, and the mixture was stirred for a further 1 h. The aqueous layer was washed with Et_2O , basified with NaOH pellets, and extracted with Et_2O . The combined organic phase was dried over MgSO_4 and filtered, and the solvent was removed under reduced pressure to afford compound **6d** as a yellow solid (40 mg, 16%). ^1H NMR (500 MHz, methanol- d_4) δ 8.07 (d, $J = 6.9$ Hz, 2H), 7.89 (br s, 2H), 7.54–7.80 (m, 3H). ^{13}C NMR (126 MHz, methanol- d_4) δ 160.8, 151.3, 142.2, 137.2, 135.8, 135.1, 134.9, 131.2, 129.0. HRMS (ESI) for $\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}_2\text{S}_2$ [$\text{M} + \text{H}$] $^+$: calculated 267.0256; observed 267.0301; error = 17 ppm.

5-(Phenylsulfonyl)thiophene-2-carboxamide (6e). A mixture of nitrile **6c** (100 mg, 0.401 mmol), InCl_3 (4.4 mg, 5%), and acetaldoxime (76 mg, 1.21 mmol) in toluene (0.4 mL) was stirred at reflux for 5 h. The solvent was removed under reduced pressure, and the crude was purified by chromatography (EtOAc/cyclohexane 20 \rightarrow 80%) to afford compound **6e** as a yellow gel (52 mg, 50%). ^1H NMR (500 MHz, CD_3OD) δ 7.94–8.10 (m, 2H), 7.66–7.75 (m, 3H), 7.59–7.66 (m, 2H). ^{13}C NMR (126 MHz, CD_3OD) δ 164.8, 148.5, 148.3, 142.9, 135.2, 134.8, 130.9, 130.2, 128.7. HRMS (ESI) for $\text{C}_{11}\text{H}_9\text{NO}_3\text{S}_2$ [$\text{M} + \text{H}$] $^+$: calculated 268.0097; observed 268.0187; error = 34 ppm.

5-(Naphthalen-2-ylsulfonyl)thiophene-2-carbaldehyde Oxime (6f). DIBAL-H (1.0 M in toluene; 1.0 mL, 1.0 mmol) was added to a solution of 5-(naphthalen-2-ylsulfonyl)thiophene-2-carbonitrile **43** (104 mg, 0.347 mmol) in DCM (3 mL) at rt. The mixture was stirred at 45 $^\circ\text{C}$ for 45 min and cooled in an ice bath. Two molar H_2SO_4 was added followed by stirring for a further 1 h at rt. The aqueous phase was extracted with DCM. The organic phase was washed with H_2O and sat. NaHCO_3 , dried over Na_2SO_4 , and

filtered, and the solvent was removed under reduced pressure. The crude was purified by column chromatography (EtOAc/cyclohexane 0 → 30%) to afford 5-(naphthalen-2-ylsulfonyl)thiophene-2-carbaldehyde as a yellow solid (96 mg, 92%). ¹H NMR (500 MHz, chloroform-*d*) δ 9.92 (s, 1H), 8.62 (s, 1H), 8.07–7.96 (m, 2H), 7.96–7.87 (m, 2H), 7.78 (d, *J* = 3.8 Hz, 1H), 7.72–7.61 (m, 3H). HRMS (ESI) for C₁₅H₁₀O₃S₂ [*M* + H]⁺: calculated 303.0144; observed 303.0159; error = 5.0 ppm.

A mixture of 5-(naphthalen-2-ylsulfonyl)thiophene-2-carbaldehyde (96 mg, 0.318 mmol), hydroxylamine hydrochloride (28 mg, 0.406 mmol), and K₂CO₃ (132 mg, 0.957 mmol) in EtOH (6.0 mL) was stirred 70 °C for 2 h. After cooling to rt, the mixture was filtered and the solvent was removed under reduced pressure. The crude was purified by chromatography (EtOAc/cyclohexane) to afford oxime **6f** as a white solid (38 mg, 38%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.61 (s, 1H), 7.95–8.08 (m, 2H), 7.87–7.95 (m, 2H), 7.58–7.74 (m, 4H), 7.41 (d, *J* = 4.1 Hz, 1H), 5.8 (br s, OH). ¹³C NMR (126 MHz, chloroform-*d*) δ 161.8, 147.8, 145.1, 137.9, 135.3, 132.8, 132.2, 129.9, 129.5, 129.3, 128.5, 128.0, 127.9, 122.3. HRMS (ESI) for C₁₅H₁₁NO₃S₂ [*M* – OH]⁺: calculated 300.0153; observed 300.0192; error = 13 ppm.

(3-(Naphthalen-2-ylsulfonyl)thiophen-2-yl)methanamine (7a). The titled compound was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 6.0 mL, 6.0 mmol), 3-(naphthalen-2-ylsulfonyl)thiophene-2-carbonitrile **52** (602 mg, 2.01 mmol), and THF (6.0 mL), for 2 h, at rt. Chromatography (EtOH/cyclohexane 0 → 90%) afforded a white crystalline solid (289 mg, 48%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.55 (d, *J* = 1.5 Hz, 1H), 8.00 (d, *J* = 7.9 Hz, 1H), 7.95 (d, *J* = 8.7 Hz, 1H), 7.90 (d, *J* = 8.0 Hz, 1H), 7.84 (dd, *J* = 8.7, 1.9 Hz, 1H), 7.69–7.60 (m, 2H), 7.42 (d, *J* = 5.4 Hz, 1H), 7.20 (d, *J* = 5.4 Hz, 1H), 4.31 (s, 2H), 1.92 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 154.77, 138.97, 135.19, 135.00, 132.29, 129.85, 129.57, 129.32, 128.68, 128.45, 128.09, 127.85, 124.02, 122.36, 40.04. HRMS (ESI) for C₁₅H₁₄NO₂S₂ ([*M* + H]⁺): calculated 304.0460; observed 304.0462; error = 0.66 ppm.

(4-(Naphthalen-2-ylsulfonyl)thiophen-3-yl)methanamine (7b). The titled compound was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 8.2 mL, 8.2 mmol), 4-(naphthalen-2-ylsulfonyl)thiophene-3-carbonitrile **54** (0.821 g, 2.75 mmol), and THF (8.2 mL); 2 h, rt. Chromatography (EtOH/cyclohexane 0 → 100%) afforded a white crystalline solid (386 mg, 47%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.55 (br, 1H), 8.27 (d, *J* = 3.4 Hz, 1H), 7.97 (d, *J* = 7.9 Hz, 1H), 7.92 (d, *J* = 8.7 Hz, 1H), 7.87 (d, *J* = 8.0 Hz, 1H), 7.79 (dd, *J* = 8.7, 1.8 Hz, 1H), 7.71–7.53 (m, 2H), 7.26 (d, *J* = 14.5 Hz, 1H), 3.85 (s, 2H), 1.82–1.54 (m, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 142.19, 138.80, 137.83, 135.08, 134.87, 132.08, 129.73, 129.46, 129.34, 128.86, 127.98, 127.79, 124.96, 122.48, 77.42, 77.17, 76.92, 40.35. HRMS (ESI) for C₁₅H₁₄NO₂S₂ ([*M* + H]⁺): calculated 304.0460; observed 304.0460; error = 0 ppm.

(4-(Naphthalen-2-ylsulfonyl)thiophen-2-yl)methanamine (7c). The titled compound was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 5.0 mL, 5.0 mmol), 4-(naphthalen-2-ylsulfonyl)thiophene-2-carbonitrile **56** (501 mg, 1.68 mmol), and THF (5.0 mL), 2 h, rt. Chromatography (EtOH/cyclohexane 5 → 100%) afforded a light orange solid (256 mg, 51%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.57 (s, 1H), 8.02 (s, 1H), 8.00–7.91 (m, 2H), 7.90–7.84 (m, 2H), 7.67–7.54 (m, 2H), 7.16 (s, 1H), 3.97 (s, 2H), 1.71 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 151.36, 141.20, 138.42, 135.07, 132.24, 130.33, 129.71, 129.44, 129.20, 128.89, 127.99, 127.70, 122.56, 121.52, 41.27. HRMS (ESI) for C₁₅H₁₄NO₂S₂ ([*M* + H]⁺): calculated 304.0460; observed 304.0444; error = 5.2 ppm.

(5-(3-(Methylsulfonyl)phenylsulfonyl)thiophen-2-yl)methanamine (8a). 5-((3-(Methylsulfonyl)phenylsulfonyl)thiophene-2-carbonitrile was synthesized according to general procedures GP4 and GP5, from (i) 5-chlorothiophene-2-carbonitrile **17a** (120 μL, 1.14 mmol), 3-(methylthio)benzenethiol (178 mg, 1.14 mmol), K₂CO₃ (157 mg, 1.14 mmol), and DMF (5.7 mL), 120 °C, 16 h and (ii) mCPBA (77%; 1.15 g, 5.13 mmol) and DCM (5.7 mL), rt,

16 h. Chromatography (EtOAc/DCM 5 → 30%) afforded a white solid (207 mg, 56%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.57 (t, *J* = 1.7 Hz, 1H), 8.28 (ddd, *J* = 7.9, 1.8, 1.1 Hz, 1H), 8.23 (ddd, *J* = 7.9, 1.6, 1.1 Hz, 1H), 7.83 (t, *J* = 7.9 Hz, 1H), 7.72 (d, *J* = 4.1 Hz, 1H), 7.60 (d, *J* = 4.1 Hz, 1H), 3.13 (s, 3H).

Compound **8a** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 0.88 mL, 0.88 mmol), 5-((3-(methylsulfonyl)phenylsulfonyl)thiophene-2-carbonitrile (96 mg, 0.293 mmol), and THF (1.5 mL); rt, 1 h. Chromatography (MeOH/DCM 0 → 20%) afforded a white solid (60 mg, 63%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.50 (t, *J* = 1.6 Hz, 1H), 8.24 (ddd, *J* = 7.9, 1.7, 1.1 Hz, 1H), 8.13 (ddd, *J* = 7.8, 1.7, 1.1 Hz, 1H), 7.74 (t, *J* = 7.9 Hz, 1H), 7.62 (d, *J* = 3.9 Hz, 1H), 6.91 (dt, *J* = 3.9, 1.0 Hz, 1H), 4.07 (d, *J* = 0.9 Hz, 2H), 3.09 (s, 3H), 1.65 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 160.00, 144.45, 142.31, 138.59, 134.88, 132.21, 131.73, 130.82, 126.38, 124.12, 44.45, 41.64. HRMS (ESI) for C₁₂H₁₁O₄S₃ ([*M* – NH₂]⁺): calculated 314.9814; observed 314.9820; error = 1.9 ppm.

(5-(2-(Methylsulfonyl)phenylsulfonyl)thiophen-2-yl)methanamine (8b). 5-((2-(Methylsulfonyl)phenylsulfonyl)thiophene-2-carbonitrile was synthesized according to general procedures GP4 and GP5, from (i) 5-chlorothiophene-2-carbonitrile **17a** (87.8 μL, 0.832 mmol), 2-(methylthio)benzenethiol (130 mg, 0.832 mmol), K₂CO₃ (172 mg, 1.25 mmol) and DMF (2.8 mL), 120 °C, 16 h and (ii) mCPBA (77%; 839 mg, 3.74 mmol) and DCM (2.8 mL), rt, 6 h. Chromatography (EtOAc/DCM 5 → 30%) afforded a white solid (46 mg, 17%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.47 (m, 1H), 8.37 (m, 1H), 7.96–7.87 (m, 3H), 7.54 (d, *J* = 4.1 Hz, 1H), 3.49 (s, 3H).

Compound **8b** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 0.41 mL, 0.41 mmol), 5-((2-(methylsulfonyl)phenylsulfonyl)thiophene-2-carbonitrile (45 mg, 0.137 mmol) and THF (0.8 mL), rt, 1 h. Chromatography (MeOH/DCM 0 → 20%) afforded compound **8b** as a white solid (17 mg, 39%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.43 (dd, *J* = 7.5, 1.7 Hz, 1H), 8.33 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.88 (d, *J* = 3.9 Hz, 1H), 7.85–7.76 (m, 2H), 6.88 (dt, *J* = 3.9, 0.9 Hz, 1H), 4.06 (d, *J* = 0.8 Hz, 2H), 3.51 (s, 3H), 1.59 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 159.33, 142.15, 139.62, 138.92, 136.80, 134.50, 134.07, 132.79, 132.44, 123.74, 45.73, 41.73. HRMS (ESI) for C₁₂H₁₄NO₄S₃ ([*M* + H]⁺): calculated 332.0080; observed 332.0108; error = 8.4 ppm.

(5-((4-(Pyrrolidin-1-ylsulfonyl)phenylsulfonyl)thiophen-2-yl)methanamine (8c). A mixture of 2,2,2-trifluoro-*N*-((5-((4-(pyrrolidin-1-ylsulfonyl)phenylthio)thiophen-2-yl)methyl)acetamide **24c** (91 mg, 0.202 mmol), mCPBA (77%; 100 mg, 0.444 mmol), and DCM (1.4 mL) was stirred at rt for 4 h. EtOAc (30 mL) was added. The organic phase was washed with sat. NaHCO₃ (3 × 30 mL), dried over MgSO₄, and filtered. The solvent was removed under reduced pressure. The crude was dissolved in 7 N NH₃ in MeOH (3.0 mL), and the mixture was stirred at rt for 16 h. The solvent was removed under reduced pressure, and the crude was purified by chromatography (EtOH/cyclohexane 5 → 40%, then 100%) to afford compound **8c** as a white solid (38 mg, 49%). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.20–8.15 (m, 2H), 8.04–8.00 (m, 2H), 7.70 (d, *J* = 3.9 Hz, 1H), 7.07 (m, 1H), 4.01 (s, 2H), 3.27–3.22 (m, 4H), 1.79–1.73 (m, 4H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 159.72, 147.61, 143.08, 140.37, 136.09, 129.69, 129.18, 126.59, 49.15, 41.66, 26.28. HRMS (ESI) for C₁₅H₁₉N₂O₄S₃ ([*M* + H]⁺): calculated 387.0502; observed 387.0489; error = 3.4 ppm.

(5-((3-(Pyrrolidin-1-ylsulfonyl)phenylsulfonyl)thiophen-2-yl)methanamine (8d). A mixture of 2,2,2-trifluoro-*N*-((5-((3-(pyrrolidin-1-ylsulfonyl)phenylthio)thiophen-2-yl)methyl)acetamide **24d** (107 mg, 0.238 mmol), mCPBA (77%; 117 mg, 0.523 mmol), and DCM (1.6 mL) was stirred at rt for 4 h. EtOAc (30 mL) was added. The organic phase was washed with sat. NaHCO₃ (3 × 30 mL), dried over MgSO₄, and filtered. The solvent was removed under reduced pressure. The crude was dissolved in 7 N NH₃ in MeOH (3.0 mL), and the mixture was stirred at rt for 16 h. The solvent was removed under reduced pressure, and the crude was purified by

chromatography (EtOH/cyclohexane 5 → 40%, then 100%) to afford compound **8d** as a white solid (49 mg, 51%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.37 (br, 1H), 8.16 (m, *J* = 7.0 Hz, 1H), 8.00 (m, *J* = 7.2 Hz, 1H), 7.69 (t, *J* = 7.8 Hz, 1H), 7.60 (m, 1H), 6.90 (br, 1H), 4.07 (br, 2H), 3.25 (br, 4H), 1.78 (br, 4H), 1.64 (br, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 159.69, 144.01, 139.17, 138.94, 134.64, 131.61, 131.00, 130.42, 126.07, 124.06, 48.17, 41.64, 25.40. HRMS (ESI) for C₁₅H₁₉N₂O₄S₃ ([M + H]⁺): calculated 387.0502; observed 387.0493; error = 2.3 ppm.

(S)-1-((3-((5-(Aminomethyl)thiophen-2-yl)sulfonyl)phenyl)sulfonyl)pyrrolidin-2-yl)methanol (8e). The titled compound was synthesized according to general procedures GP5 and GP3, from (i) (S)-5-((3-((2-(hydroxymethyl)pyrrolidin-1-yl)sulfonyl)phenyl)thio)thiophene-2-carbonitrile **23e** (180 mg, 0.474 mmol), mCPBA (77%; 234 mg, 1.04 mmol) and DCM (3.2 mL), rt, 3 h and (ii) BH₃ (1.0 M in THF; 1.42 mL, 1.42 mmol) and THF (1.42 mL), rt, 1 h. Chromatography (EtOH/cyclohexane 20 → 100%) afforded a white foam (141 mg, 72%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.37 (t, *J* = 1.8 Hz, 1H), 8.18 (dt, *J* = 7.9, 1.5 Hz, 1H), 8.02 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.70 (t, *J* = 7.9 Hz, 1H), 7.60 (d, *J* = 3.8 Hz, 1H), 6.91 (m, 1H), 4.07 (d, *J* = 1.0 Hz, 2H), 3.69–3.58 (m, 3H), 3.45 (ddd, *J* = 10.4, 6.9, 5.2 Hz, 1H), 3.18 (dt, *J* = 10.4, 7.1 Hz, 1H), 2.13 (br, 3H), 1.88–1.75 (m, 2H), 1.70–1.58 (m, 1H), 1.55–1.43 (m, 1H). ¹³C NMR (126 MHz, chloroform-*d*) δ 159.51, 144.04, 139.01, 138.72, 134.73, 131.69, 131.20, 130.61, 126.10, 124.24, 65.27, 62.06, 50.01, 41.54, 28.72, 24.26. HRMS (ESI) for C₁₆H₂₀N₂O₅S₃Na ([M + Na]⁺): calculated 439.0427; observed 439.0413; error = 3.2 ppm.

5-((4-(Phenylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methanamine (8f). The titled compound was synthesized according to general procedure GP3, from 5-((4-(phenylsulfonyl)phenyl)sulfonyl)thiophene-2-carbonitrile **30** (40 mg, 0.103 mmol), BH₃ (1.0 M in THF; 0.5 mL, 0.5 mmol), and THF (4.0 mL), rt, 3 h. Chromatography (EtOH/cyclohexane 0 → 100%) afforded a glassy solid (8 mg, 20%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.21–8.13 (m, 4H), 7.99 (dt, *J* = 7.1, 1.3 Hz, 2H), 7.75 (d, *J* = 3.9 Hz, 1H), 7.73–7.70 (m, 1H), 7.64 (t, *J* = 7.8 Hz, 2H), 7.02 (dt, *J* = 3.5, 1.2 Hz, 1H), 3.89 (d, *J* = 1.3 Hz, 2H), 2.45–2.13 (br, 2H). HRMS calcd for C₁₇H₁₅NO₄S₃ [M + H]⁺ 394.0236; found 394.0233; error = 0.76 ppm.

2-((4-((5-(Aminomethyl)thiophen-2-yl)sulfonyl)phenyl)sulfonyl)ethanol Hydrochloride (8g). The titled compound was synthesized according to general procedures GP2, from *tert*-butyl ((5-((4-((2-hydroxyethyl)sulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate **27** (*n* = 1) (52 mg, 0.113 mmol) and 4 M HCl in dioxane (3.0 mL); rt, 3 h. A white solid was obtained, which did not require further purification (39 mg, 87%). ¹H NMR (500 MHz, D₂O) δ 8.37–8.29 (m, 2H), 8.27–8.19 (m, 2H), 7.91 (m, 1H), 7.38 (m, 1H), 4.48 (s, 2H), 4.03–3.95 (m, 2H), 3.72–3.65 (m, 2H). ¹³C NMR (126 MHz, D₂O) δ 146.18, 144.20, 140.94, 136.69, 131.43, 130.19, 129.18, 58.15, 55.77, 38.19. HRMS (ESI) for C₁₃H₁₃O₅S₃ ([M – NH₂]⁺): calculated 344.9920; observed 344.9917; error = 0.87 ppm.

3-((4-((5-(Aminomethyl)thiophen-2-yl)sulfonyl)phenyl)sulfonyl)propan-1-ol Hydrochloride (8h). The titled compound was synthesized according to general procedure GP2, from 4 M HCl in dioxane (1.5 mL) and *tert*-butyl ((5-((4-((3-hydroxypropyl)sulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate **27** (*n* = 2) 23.5 mg, 0.0494 mmol; rt, 3 h. A white solid was obtained and did not require further purification (23 mg, quant.). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.26 (d, *J* = 8.5 Hz, 2H), 8.15 (d, *J* = 8.5 Hz, 2H), 7.83 (d, *J* = 3.9 Hz, 1H), 7.34 (d, *J* = 3.9 Hz, 1H), 4.39 (s, 2H), 3.58 (t, *J* = 6.1 Hz, 2H), 3.37–3.32 (m, 2H), 1.89–1.80 (m, 2H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 148.02, 146.19, 145.44, 144.33, 136.14, 131.84, 130.66, 129.60, 60.56, 53.60, 38.46, 26.85. HRMS (ESI) for C₁₄H₁₈NO₅S₃ ([M + H]⁺): calculated 376.0342; observed 376.0334; error = 2.1 ppm.

5-((4-((2-(Pyrrolidin-1-yl)ethyl)sulfonyl)phenyl)sulfonyl)thiophen-2-yl)methanamine Dihydrochloride (8i). Pyrrolidine (12.6 μL, 0.151 mmol) was added to a solution of *tert*-butyl ((5-((4-(vinylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate **28** (61 mg, 0.138 mmol) in DCM (0.8 mL), and the mixture was

stirred at rt for 16 h. The solvent was removed under reduced pressure. Four molar HCl in dioxane (4 mL) was added to the crude and the mixture was stirred at rt for 16 h. The precipitated solid was collected on a pad of celite and washed with EtOAc. MeOH was added to dissolve the solid, and the suspension was filtered. The solvent was removed under reduced pressure to afford compound **8i** as a white solid (58 mg, 85%), which did not require further purification. ¹H NMR (500 MHz, D₂O) δ 8.37 (d, *J* = 7.9 Hz, 2H), 8.27 (d, *J* = 7.9 Hz, 2H), 7.92 (m, 1H), 7.41 (m, 1H), 4.51 (s, 2H), 3.99 (t, *J* = 7.2 Hz, 2H), 3.92–2.98 (m, 6H), 2.13 (br, 4H). ¹³C NMR (126 MHz, D₂O) δ 146.87, 145.89, 142.50, 140.91, 136.88, 131.77, 130.49, 129.53, 55.66, 51.65, 48.16, 38.08, 23.47. HRMS (ESI) for C₁₇H₂₃N₂O₄S₃ ([M + H]⁺): calculated 415.0815; observed 415.0828; error = 3.1 ppm.

N-2-((4-((5-(Aminomethyl)thiophen-2-yl)sulfonyl)phenyl)sulfonyl)ethyl)acetamide Hydrochloride (8j). A mixture of *tert*-butyl ((5-((4-(vinylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate **28** (448 mg, 1.01 mmol) and 7 N NH₃ in MeOH (10 mL) was stirred at rt for 2 h. The solvent was removed under reduced pressure to afford *tert*-butyl ((5-((4-((2-aminoethyl)sulfonyl)phenyl)thio)thiophen-2-yl)methyl)carbamate as a white solid (472 mg, quant.), which did not require further purification. ¹H NMR (500 MHz, methanol-*d*₄) δ 7.70 (d, *J* = 3.8 Hz, 1H), 7.03 (d, *J* = 3.9 Hz, 1H), 4.39 (s, 2H), 8.16–8.12 (m, 2H), 3.39 (t, *J* = 6.7 Hz, 2H), 2.96 (t, *J* = 6.7 Hz, 2H), 1.44 (s, 9H), 8.27–8.21 (m, 2H). LCMS (ESI) *m/z* 405 [M – ^tBu + 2H]⁺.

Ac₂O (18.1 μL, 0.191 mmol) was added to a solution of afford *tert*-butyl ((5-((4-((2-aminoethyl)sulfonyl)phenyl)thio)thiophen-2-yl)methyl)carbamate (80 mg, 0.174 mmol) and Et₃N (29.1 μL, 0.209 mmol) in DCM (1.2 mL), and the mixture was stirred at rt for 1 h. DCM (20 mL) was added. The organic solution was washed with H₂O (20 mL) and brine (20 mL), dried over MgSO₄, and filtered, and the solvent was removed under reduced pressure. Four molar HCl in dioxane (5.0 mL) was added to the crude, and the mixture was stirred at rt for 16 h. The precipitated solid was filtered through a pad of celite and washed with EtOAc. MeOH was added to dissolve the solid, and the suspension was filtered. The solvent was removed under reduced pressure to afford compound **8j** as a white solid (42 mg, 55%), which did not require further purification. ¹H NMR (500 MHz, methanol-*d*₄) δ 8.26 (d, *J* = 8.5 Hz, 2H), 8.15 (d, *J* = 8.6 Hz, 2H), 7.83 (d, *J* = 3.9 Hz, 1H), 7.34 (d, *J* = 3.8 Hz, 1H), 4.39 (s, 2H), 3.57–3.44 (m, 4H), 1.69 (s, 3H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 173.41, 148.05, 146.22, 145.69, 144.29, 136.17, 131.85, 130.69, 129.58, 54.98, 38.43, 34.81, 22.23. HRMS (ESI) for C₁₅H₁₉N₂O₅S₃ ([M + H]⁺): calculated 403.0451; observed 403.0453; error = 0.50 ppm.

5-((4-((2-Methoxyethyl)sulfonyl)phenyl)sulfonyl)thiophen-2-yl)methanamine Hydrochloride (8k). A mixture of *tert*-butyl ((5-((4-(vinylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate **28** (65.9 mg, 0.149 mmol), K₂CO₃ (24.6 mg, 0.178 mmol), and MeOH (1 mL) was stirred at rt for 2 h before it was diluted with EtOAc (20 mL). The organic layer was washed with 1:1 H₂O/brine (20 mL), dried over MgSO₄, and filtered, and the solvent was removed under reduced pressure. Four molar HCl in dioxane (5 mL) was added to the crude, and the mixture was stirred at rt for 3 h. The precipitated solid was filtered through a pad of celite and washed with EtOAc. MeOH was added to dissolve the solid, and the suspension was filtered. The solvent was removed under reduced pressure to afford compound **8k** as a white solid (30 mg, 54%) which did not require further purification. ¹H NMR (500 MHz, methanol-*d*₄) δ 8.22 (d, *J* = 8.6 Hz, 2H), 8.13 (d, *J* = 8.6 Hz, 2H), 7.83 (d, *J* = 3.9 Hz, 1H), 7.33 (d, *J* = 3.9 Hz, 1H), 4.39 (s, 2H), 3.72 (t, *J* = 5.6 Hz, 2H), 3.55 (t, *J* = 5.6 Hz, 2H), 3.11 (s, 3H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 147.77, 146.76, 146.08, 144.50, 136.04, 131.78, 130.69, 129.24, 66.83, 58.69, 56.78, 38.43. HRMS (ESI) for C₁₄H₁₈NO₅S₃ ([M + H]⁺): calculated 376.0342; observed 376.0333; error = 2.4 ppm.

5-((3-(*tert*-Butyl)-5-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methanamine (9a). To a solution of carbalddehyde **33** (590 mg, 1.66 mmol) in THF (50 mL) at 0 °C was added sodium

borohydride (141 mg, 3.72 mmol). The reaction mixture was stirred at rt for 2 h, before it was quenched with ice. The pH of the solution was adjusted to 4–5 with 1 M HCl, and the aqueous phase was extracted with EtOAc. The combined organic phase was washed with brine, dried over Na₂SO₄, and filtered, and the solvent was removed under reduced pressure. The crude was dissolved in DCM (50 mL). mCPBA (77%; 742 mg, 3.31 mmol) was added in small portions at 0 °C. The mixture was stirred at rt for 12 h, and the solvent was subsequently removed under reduced pressure. The crude was purified by chromatography (EtOAc/cyclohexane 0 → 60%) to afford 5-((3-(*tert*-butyl)-5-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methanol (500 mg, 78% over two steps). ¹H NMR (500 MHz, chloroform-*d*) δ 8.32 (t, *J* = 1.4 Hz, 1H), 8.27 (t, *J* = 1.7 Hz, 1H), 8.13 (t, *J* = 1.6 Hz, 1H), 7.65 (d, *J* = 3.8 Hz, 1H), 6.99 (d, *J* = 3.8 Hz, 1H), 4.87 (s, 2H), 3.10 (s, 3H), 2.24 (br, 1H), 1.40 (s, 9H). ¹³C NMR (126 MHz, chloroform-*d*) δ 155.4, 155.3, 143.8, 142.0, 140.2, 134.3, 129.1, 128.7, 125.0, 123.7, 60.1, 44.4, 35.8, 31.0. HRMS (ESI) for C₁₆H₁₉O₄S₃ ([M – OH]⁺): calculated 371.0445; observed 371.0486.

To a solution of 5-((3-(*tert*-butyl)-5-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methanol (500 mg, 1.29 mmol) in THF (15 mL) at 0 °C was added PPh₃ (406 mg, 1.54 mmol) and DEAD (0.24 mL, 1.54 mmol). The mixture was stirred at 0 °C for 10 min, followed by the addition of DPPA (0.35 mL, 1.54 mmol). The reaction was warmed to rt over 16 h, and the solvent was removed under reduced pressure. The crude was dissolved in EtOH (50 mL), and Pd/C (10%; 150 mg) was added. The mixture was stirred at rt under H₂ pressure (balloon) for 12 h and then filtered through celite. The solvent was removed under reduced pressure, and the crude was purified by chromatography (EtOH/cyclohexane 0 → 100%) to afford compound **9a** as an orange gum (262 mg, 52%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.28 (t, *J* = 1.4 Hz, 1H), 8.23 (t, *J* = 1.6 Hz, 1H), 8.09 (t, *J* = 1.6 Hz, 1H), 7.60 (d, *J* = 3.8 Hz, 1H), 6.90 (d, *J* = 3.8 Hz, 1H), 4.06 (s, 2H), 3.08 (s, 3H), 1.70 (br, 2H), 1.36 (s, 9H). ¹³C NMR (126 MHz, chloroform-*d*) δ 159.4, 155.2, 143.9, 141.8, 138.6, 134.5, 128.9, 128.4, 123.9, 123.5, 44.3, 41.4, 35.6, 30.9. HRMS (ESI) for C₁₆H₁₉O₄S₃ ([M – H]⁺): calculated 371.0445; observed 371.0428; error = 4.6 ppm.

5-((3-(*tert*-Butoxy)-5-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methanamine (9b). NaO^tBu (65.8 mg, 0.684 mmol) was added to a degassed mixture of 2-ethylhexyl 3-((3-(*tert*-butoxy)-5-(methylthio)phenyl)thio)propanoate **60** (282 mg, 0.684 mmol) and 5-bromothiophene-2-carbonitrile **17a** (76.1 μL, 0.684 mmol) in DMF (3.4 mL), and the mixture was stirred at 60 °C for 3h. The cooled mixture was diluted with EtOAc (50 mL), washed with H₂O (3 × 50 mL) and brine (50 mL), dried over MgSO₄, and filtered. The solvent was removed under reduced pressure, and the crude was purified by chromatography (EtOAc/pet ether 0 → 10%) to afford 5-((3-(*tert*-Butoxy)-5-(methylthio)phenyl)thio)thiophene-2-carbonitrile as a colorless oil (85 mg, 37%). ¹H NMR (300 MHz, chloroform-*d*) δ 7.51 (d, *J* = 3.9 Hz, 1H), 7.12 (d, *J* = 3.9 Hz, 1H), 6.94 (t, *J* = 1.7 Hz, 1H), 6.79 (t, *J* = 1.9 Hz, 1H), 6.72 (t, *J* = 1.9 Hz, 1H), 2.44 (s, 3H), 1.33 (s, 9H). LCMS (ESI) *m/z* 280 [M – ^tBu + 2H]⁺.

5-((3-(*tert*-Butoxy)-5-(methylsulfonyl)phenyl)sulfonyl)thiophene-2-carbonitrile was synthesized according to general procedure GP5, from 5-((3-(*tert*-Butoxy)-5-(methylthio)phenyl)thio)thiophene-2-carbonitrile (41 mg, 0.122 mmol), mCPBA (70–75%; 145 mg, 0.612 mmol) and DCM (1.2 mL), rt, 16 h. Chromatography (EtOAc/cyclohexane 0 → 60%) afforded a white solid (43 g, 88%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.17 (t, *J* = 1.6 Hz, 1H), 7.81 (dd, *J* = 2.2, 1.7 Hz, 1H), 7.76 (dd, *J* = 2.2, 1.6 Hz, 1H), 7.71 (d, *J* = 4.0 Hz, 1H), 7.60 (d, *J* = 4.1 Hz, 1H), 3.10 (s, 3H), 1.46 (s, 9H). LCMS (ESI, -ve) *m/z* 398 [M – H]⁻.

Compound **9b** was synthesized according to general procedure GP3, from BH₃ (1.0 M in THF; 0.53 mL, 0.53 mmol), 5-((3-(*tert*-Butoxy)-5-(methylsulfonyl)phenyl)sulfonyl)thiophene-2-carbonitrile (70 mg, 0.175 mmol) and THF (0.53 mL), 2 h, rt. Chromatography (EtOH/cyclohexane 30, then 100%) afforded a white foam (60 mg, 85%). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.14 (t, *J* = 1.6 Hz, 1H), 7.81 (m, 1H), 7.79–7.74 (m, 2H), 7.15 (m, 1H), 4.10 (s, 2H), 3.20

(s, 3H), 1.44 (s, 9H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 158.93, 157.22, 146.05, 144.77, 140.99, 136.12, 127.67, 126.97, 126.78, 120.47, 82.68, 43.97, 41.02, 28.83. HRMS (ESI) for C₁₆H₂₂NO₅S₃ ([M + H]⁺): calculated 404.0655; observed 404.0651; error = 0.99 ppm.

5-((3-(Methylsulfonyl)-5-((trimethylsilyl)ethynyl)phenyl)sulfonyl)thiophen-2-yl)methanamine Hydrochloride (9c). A mixture of *tert*-butyl ((5-((3-bromo-5-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate **34** (170 mg, 0.333 mmol), Pd(PPh₃)₄ (38.5 mg, 10%), CuI (12.7 mg, 20%), trimethylsilylacetylene (70.6 μL, 0.500 mmol), Et₃N (0.5 mL), and 1,4-dioxane (0.5 mL) was degassed with argon and then stirred at rt for 16 h. The solvent was removed under reduced pressure, and the crude was dissolved in DCM (1.0 mL). Four molar HCl in dioxane (1.0 mL) was added, and the mixture was stirred at rt for 16 h. EtOAc (2.0 mL) was added to precipitate the solids, which were filtered, washed with EtOAc, and dried under vacuum to afford compound **9c** as white powder (80 mg, 88%). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.42 (H, 1H), 8.29–8.21 (m, 2H), 7.88 (d, *J* = 3.7 Hz, 1H), 7.33 (d, *J* = 3.8 Hz, 1H), 4.39 (s, 2H), 3.21 (s, 3H), 0.28 (s, 9H). ¹³C NMR (126 MHz, methanol-*d*₄) δ 146.34, 145.18, 144.58, 143.96, 136.34, 136.15, 135.52, 131.87, 127.82, 126.41, 101.83, 54.75, 43.85, 38.40. HRMS (ESI) for C₁₇H₂₂NO₄S₃Si ([M + H]⁺): calculated 428.0475; observed 428.0477; error = 0.47 ppm.

5-((3-(1-Methyl-1H-pyrazol-4-yl)-5-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methanamine (9d). The titled compound was synthesized according to general procedures GP7 and GP2, from (i) *tert*-butyl ((5-((3-bromo-5-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate **34** (100 mg, 0.196 mmol), Pd(PPh₃)₄ (22.6 mg, 10%), (1-methyl-1H-pyrazol-4-yl)boronic acid pinacol ester (48.9 mg, 0.235 mmol), Cs₂CO₃ (76.7 mg, 0.235 mmol), and 1,4-dioxane (1.3 mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (1.0 mL) and DCM (1.0 mL), rt, 3 h. The crude was basified with 2 N NH₃ in MeOH and purified by chromatography (MeOH/DCM 0 → 25%) to afford a light yellow solid (57 mg, 71%). ¹H NMR (500 MHz, methanol-*d*₄/chloroform-*d*) δ 8.29 (t, *J* = 1.7 Hz, 1H), 8.27–8.22 (m, 2H), 8.07 (s, 1H), 7.91 (s, 1H), 7.69 (d, *J* = 3.9 Hz, 1H), 7.04 (d, *J* = 3.7 Hz, 1H), 4.04 (s, 2H), 3.95 (s, 3H), 3.18 (s, 3H). ¹³C NMR (126 MHz, methanol-*d*₄/chloroform-*d*) δ 157.51, 145.17, 143.55, 139.75, 137.56, 137.06, 135.61, 129.87, 128.63, 128.57, 126.43, 123.50, 120.52, 44.25, 41.01, 39.31. HRMS (ESI) for C₁₆H₁₈N₃O₄S₃ ([M + H]⁺): calculated 412.0454; observed 412.0444; error = 2.4 ppm.

5-((3-(Methylsulfonyl)-5-(pyridin-4-yl)phenyl)sulfonyl)thiophen-2-yl)methanamine (9e). The titled compound was synthesized according to general procedures GP7 and GP2, from (i) *tert*-butyl ((5-((3-bromo-5-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate **34** (100 mg, 0.196 mmol), Pd(PPh₃)₄ (45.2 mg, 20%), pyridine-4-boronic acid (57.8 mg, 0.470 mmol), Cs₂CO₃ (76.7 mg, 0.235 mmol), and 1,4-dioxane (1.3 mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (0.6 mL) and 1,4-dioxane (0.6 mL), rt, 16 h. The crude was basified with 2 N NH₃ in MeOH and purified by chromatography (MeOH/DCM 0 → 20%) to afford a yellow solid (35 mg, 44%). ¹H NMR (500 MHz, methanol-*d*₄/chloroform-*d*) δ 8.72–8.69 (m, 2H), 8.55 (t, *J* = 1.6 Hz, 1H), 8.50 (t, *J* = 1.6 Hz, 1H), 8.45 (t, *J* = 1.6 Hz, 1H), 7.73–7.70 (m, 3H), 7.04 (d, *J* = 3.9 Hz, 1H), 4.04 (s, 2H), 3.23 (s, 3H). ¹³C NMR (126 MHz, methanol-*d*₄/chloroform-*d*) δ 158.47, 150.06, 145.33, 145.14, 143.36, 141.22, 138.23, 135.26, 130.28, 130.21, 126.22, 125.35, 122.13, 43.68, 40.64. HRMS (ESI) for C₁₇H₁₇N₂O₄S₃ ([M + H]⁺): calculated 409.0345; observed 409.0340; error = 1.2 ppm.

5-((4'-Methyl-5-(methylsulfonyl)-[1,1'-biphenyl]-3-yl)sulfonyl)thiophen-2-yl)methanamine (9g). The titled compound was synthesized according to general procedures GP7 and GP2, from (i) *tert*-butyl ((5-((3-bromo-5-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate **34** (100 mg, 0.196 mmol), Pd(PPh₃)₄ (22.6 mg, 10%), *p*-tolyl boronic acid (32.0 mg, 0.235 mmol), Cs₂CO₃ (76.7 mg, 0.235 mmol), and 1,4-dioxane (1.3 mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (1.0 mL) and DCM (1.0 mL), rt, 3 h. The crude was basified with 2 N NH₃ in MeOH and purified by

chromatography (acetone/DCM 0 → 40%) to afford a light yellow foam (20 mg, 24%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.45–8.39 (m, 2H), 8.30 (t, *J* = 1.6 Hz, 1H), 7.67 (d, *J* = 3.9 Hz, 1H), 7.54 (d, *J* = 8.2 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 6.93 (d, *J* = 3.9 Hz, 1H), 4.09 (s, 2H), 3.14 (s, 3H), 2.44 (s, 3H), 1.61 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 144.95, 144.56, 142.77, 139.79, 138.73, 134.92, 134.43, 130.27, 130.15, 129.73, 127.25, 124.34, 124.16, 44.59, 41.71, 21.36. HRMS (ESI) for C₁₉H₂₀NO₄S₃ ([M + H]⁺): calculated 422.0549; observed 422.0561; error = 2.8 ppm.

5-((3',5'-Dimethyl-5-(methylsulfonyl)-[1,1'-biphenyl]-3-yl)-sulfonyl)thiophen-2-yl)methanamine Hydrochloride (9h). The titled compound was synthesized according to general procedures GP7 and GP2, from (i) *tert*-butyl ((5-((3-bromo-5-(methylsulfonyl)-phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 34 (100 mg, 0.196 mmol), Pd(PPh₃)₄ (22.6 mg, 10%), (3,5-dimethylphenyl)boronic acid (35.3 mg, 0.235 mmol), Cs₂CO₃ (76.7 mg, 0.235 mmol), and 1,4-dioxane (1.3 mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (0.7 mL) and 1,4-dioxane (0.7 mL), rt, 16 h. The crude was basified with 2 N NH₃ in MeOH and purified by chromatography (EtOH/cyclohexane 0 → 100% then 100%) to afford a white solid (23 mg, 27%). ¹H NMR (500 MHz, methanol-*d*₄/chloroform-*d*) δ 8.41–8.35 (m, 2H), 8.30 (t, *J* = 1.6 Hz, 1H), 7.68 (d, *J* = 3.9 Hz, 1H), 7.22 (br, 2H), 7.09 (br, 1H), 7.03 (d, *J* = 3.8 Hz, 1H), 4.04 (s, 2H), 3.17 (s, 3H), 2.38 (s, 6H). ¹³C NMR (126 MHz, methanol-*d*₄/chloroform-*d*) δ 145.50, 144.81, 143.06, 139.62, 139.57, 137.51, 135.39, 131.47, 130.63, 130.52, 126.17, 125.50, 124.57, 44.43, 40.89, 21.44. HRMS (ESI) for C₂₀H₂₂NO₄S₃ ([M + H]⁺): calculated 436.0705; observed 436.0700; error = 1.1 ppm.

5-((2'-Ethyl-5-(methylsulfonyl)-[1,1'-biphenyl]-3-yl)-sulfonyl)thiophen-2-yl)methanamine Hydrochloride (9i). The titled compound was synthesized according to general procedures GP7 and GP2, from (i) *tert*-butyl ((5-((3-bromo-5-(methylsulfonyl)-phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 34 (100 mg, 0.196 mmol), Pd(PPh₃)₄ (22.6 mg, 10%), (2-ethylphenyl)boronic acid (35.3 mg, 0.235 mmol), Cs₂CO₃ (76.7 mg, 0.235 mmol), and 1,4-dioxane (1.3 mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (0.7 mL) and 1,4-dioxane (0.7 mL), rt, 16 h. The crude was basified with 2 N NH₃ in MeOH and purified by chromatography (EtOH/cyclohexane 0 → 100% then 100%) to afford a white foam (42 mg, 49%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.49 (t, *J* = 1.7 Hz, 1H), 8.21 (t, *J* = 1.6 Hz, 1H), 8.09 (t, *J* = 1.6 Hz, 1H), 7.66 (d, *J* = 3.8 Hz, 1H), 7.42 (td, *J* = 7.6, 1.3 Hz, 1H), 7.37 (m, 1H), 7.30 (td, *J* = 7.4, 1.4 Hz, 1H), 7.18 (dd, *J* = 7.6, 1.2 Hz, 1H), 6.94 (d, *J* = 3.9 Hz, 1H), 4.10 (s, 2H), 3.14 (s, 3H), 2.53 (q, *J* = 7.5 Hz, 2H), 1.61 (s, 2H), 1.12 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (126 MHz, chloroform-*d*) δ 159.97, 145.25, 144.31, 142.19, 141.50, 138.66, 137.63, 134.95, 132.72, 132.24, 129.87, 129.41, 129.33, 126.37, 124.59, 124.15, 44.53, 41.73, 26.17, 15.73. HRMS (ESI) for C₂₀H₂₂NO₄S₃ ([M + H]⁺): calculated 436.0705; observed 436.0727; error = 5.0 ppm.

5-((3-(1-Methyl-1H-pyrazol-4-yl)-4-(methylsulfonyl)-phenyl)sulfonyl)thiophen-2-yl)methanamine Dihydrochloride (9j). The titled compound was synthesized according to general procedures GP7 and GP2, from (i) *tert*-butyl ((5-((3-bromo-4-(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 37 (150 mg, 0.294 mmol), Pd(PPh₃)₄ (34.0 mg, 10%), (1-methyl-1H-pyrazol-4-yl)boronic acid pinacol ester (73.0 mg, 0.353 mmol), Cs₂CO₃ (115 mg, 0.353 mmol), and 1,4-dioxane (2.0 mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (1.5 mL) and DCM (1.5 mL), rt, 3 h. A white solid was obtained (111 mg, 92%). ¹H NMR (500 MHz, D₂O) δ 8.32 (d, *J* = 8.5 Hz, 1H), 8.16 (dd, *J* = 8.6, 2.2 Hz, 1H), 8.05 (d, *J* = 1.9 Hz, 1H), 7.92 (s, 1H), 7.84 (d, *J* = 4.0 Hz, 1H), 7.74 (s, 1H), 7.33 (d, *J* = 4.0 Hz, 1H), 4.44 (s, 2H), 3.96 (s, 3H), 2.96 (s, 3H). ¹³C NMR (126 MHz, D₂O) δ 144.87, 144.70, 142.07, 140.32, 139.70, 135.77, 134.00, 132.82, 131.38, 130.83, 130.08, 126.31, 116.55, 41.49, 38.31, 37.18. HRMS (ESI) for C₁₆H₁₈N₃O₄S₃ ([M + H]⁺): calculated 412.0454; observed 412.0441; error = 3.2 ppm.

5-((6-(Methylsulfonyl)-[1,1'-biphenyl]-3-yl)sulfonyl)thiophen-2-yl)methanamine (9k). The titled compound was synthesized according to general procedures GP7 and GP2, from (i) *tert*-butyl ((5-((3-bromo-4-(methylsulfonyl)phenyl)sulfonyl)-

thiophen-2-yl)methyl)carbamate 37 (150 mg, 0.294 mmol), Pd(PPh₃)₄ (34.0 mg, 10%), phenylboronic acid (43.1 mg, 0.353 mmol), Cs₂CO₃ (115 mg, 0.353 mmol), and 1,4-dioxane (2.0 mL), 90 °C, 16 h. Chromatography (EtOAc/DCM 0 → 100%), white foam, 169 mg and (ii) 4 M HCl in dioxane (1.0 mL) and DCM (1.0 mL), rt, 3 h. The crude was basified with 2 N NH₃ in MeOH and purified by chromatography (EtOH/cyclohexane 0 → 100%) to afford a white solid (66 mg, 55%). ¹H NMR (500 MHz, chloroform-*d*) δ 8.37 (d, *J* = 8.3 Hz, 1H), 8.11 (dd, *J* = 8.3, 1.9 Hz, 1H), 7.97 (d, *J* = 2.0 Hz, 1H), 7.63 (d, *J* = 3.9 Hz, 1H), 7.55–7.41 (m, 5H), 6.93 (d, *J* = 3.8 Hz, 1H), 4.10 (s, 2H), 2.61 (s, 3H), 1.63 (s, 2H). ¹³C NMR (126 MHz, chloroform-*d*) δ 160.04, 146.65, 143.39, 142.92, 138.54, 136.79, 134.97, 131.05, 130.11, 129.70, 129.38, 128.43, 126.64, 124.12, 43.13, 41.67. HRMS (ESI) for C₁₈H₁₈NO₄S₃ ([M + H]⁺): calculated 408.0392; observed 408.0373; error = 4.9 ppm.

5-((4'-Methyl-6-(methylsulfonyl)-[1,1'-biphenyl]-3-yl)-sulfonyl)thiophen-2-yl)methanamine Hydrochloride (9l). The titled compound was synthesized according to general procedures GP7 and GP2, from (i) *tert*-butyl ((5-((3-bromo-4-(methylsulfonyl)-phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 37 (150 mg, 0.294 mmol), Pd(PPh₃)₄ (34.0 mg, 10%), *p*-tolyl boronic acid (48.0 mg, 0.353 mmol), Cs₂CO₃ (115 mg, 0.353 mmol), and 1,4-dioxane (2.0 mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (1.5 mL) and DCM (1.5 mL), rt, 3 h. A beige solid obtained (83 mg, 62% over). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.37 (d, *J* = 8.4 Hz, 1H), 8.22 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.91 (d, *J* = 2.0 Hz, 1H), 7.83 (d, *J* = 3.9 Hz, 1H), 7.36–7.30 (m, 5H), 4.40 (s, 2H), 2.70 (s, 3H), 2.43 (s, 3H). ¹³C NMR (75 MHz, methanol-*d*₄) δ 147.21, 146.24, 145.44, 144.69, 144.29, 140.60, 136.19, 135.39, 132.22, 131.88, 131.03, 130.92, 129.94, 127.81, 43.41, 38.43, 21.30. HRMS (ESI) for C₁₉H₂₀NO₄S₃ ([M + H]⁺): calculated 422.0549; observed 422.0531; error = 4.3 ppm.

Pan Assay Interference Compound (PAINS) Assessment. To identify compounds that may demonstrate some degree of promiscuity in biochemical screening, the PAINS filters as described by Baell and Holloway²³ were curated as SMARTS and scripted as a flagging protocol deployed in Vortex (version 2018.09.76561.53-s, 2018, <https://www.dotmatics.com/products/vortex>) and Pipeline Pilot (Dassault Systèmes BIOVIA, BIOVIA Pipeline Pilot, Release 2018, San Diego: Dassault Systèmes, 2018). The 480 patterns were used to recognize structures that may result in nonspecific binding to multiple biological targets by virtue of being comprised of one or more fragments established to be of concern. No LOX inhibitor in this study showed any potential PAINS liability when screened against this PAINS filter.

LOX Protein Preparation and Enzyme Assay. LOX enzyme was extracted from pig skin by the method of Shackleton and Hulmes.²⁴ LOX catalytic activity was determined using a horseradish peroxidase (HRP)-coupled fluorescent assay previously described,¹⁹ with cadaverine hydrochloride as a substrate, BAPN as positive control, and a preincubation time of 20 min with nine dilutions from a top concentration of 100 μM. LOXL2 was purchased from R&D System. LOXL2 catalytic activity was determined using the Promega ROS-Glo assay kit with cadaverine hydrochloride as a substrate, BAPN as positive control, and a preincubation time of 20 min at the same concentrations as above.

High-Throughput Screening. HTS was performed by Evotec AG on 270 000 diverse compounds and 5000 fragments using the enzyme assay described above.

Amine Oxidase Assays. Methods for the determination of catalytic activity of DAO, MAO-A, and MAO-B have been previously described.¹⁹ All amine oxidase assays were performed with concentrations as above. MAO-A and MAO-B enzymes were purchased from Promega and Sigma, respectively. The catalytic activity of MAO-A and MAO-B was determined using the Promega MAO-Glo assay kit (substrate included), with clorgyline and deprenyl as positive controls, respectively. DAO was purchased from Sigma and the catalytic activity was determined using the Promega ROS-Glo assay kit, with aminoguanidine as the positive control. SSAO was purchased from Sigma. SSAO catalytic activity was determined using the Promega MAO-Glo assay kit, with Mofegiline as positive control.

Assessment of Compound 9f as a Substrate for Amine Oxidases. The catalytic activities of MAO-A, MAO-B, and SSAO with compound 9f as a substrate were determined using the respective enzymes described above, and the hydrogen peroxide produced was quantified using the HRP-coupled fluorescent method as in the LOX activity assay.

MLM Stability Assay. Mouse liver microsomes (BALB/c) were purchased from Tebu-bio, and the assay was performed by methods previously described.¹⁹ Inhibitors at 10 μ M concentration incubated with the microsomes were assessed at 0, 15, and 30 min. Control samples containing no microsomes and no cofactors were also assessed at 0 and 30 min. Samples were extracted by protein precipitation and centrifugation for 20 min in a refrigerated centrifuge (4 °C) at 3700 rpm. The supernatant was analyzed by LCMS/MS for % metabolized over time.

In Vivo PK. All procedures involving animals were performed in accordance with national Home Office regulations under the Animals (Scientific Procedures) Act 1986 and within guidelines set out by the Institute's Animal Ethics Committee and the United Kingdom Coordinating Committee for Cancer Research's ad hoc Committee on the Welfare of Animals in Experimental Neoplasia.²⁵ Female BALB/c or CD1 mice (Charles River Laboratories) at 6 weeks of age were used for the PK analyses. The mice were dosed orally by gavage (50 mg/kg in dimethyl sulfoxide (DMSO)/water 1:19 v/v; $n = 21$) or intravenously in the tail vein (10 mg/kg in DMSO/Tween20/saline 10:1:89 v/v/v; $n = 24$). Samples were taken at seven (po) or eight (iv) time points between 5 min and 24 h. Three mice were used per time point per route. They were placed under halothane or isoflurane anesthesia, and blood for plasma preparation was taken by terminal cardiac puncture into heparinized syringes. Plasma samples were snap-frozen in liquid nitrogen and then stored at -80 °C prior to analysis.

In Vivo Anti-metastatic Efficacy. LOX inhibitor treatment was carried out in mouse GEMM breast cancer model where MMTV-PyMT female mice were randomized as described previously.¹⁹ Mice were treated daily by oral gavage with 70 mg/kg compound 9f ($n = 5$) in vehicle (5% DMSO/2.5% Tween20 in water) or control with vehicle alone ($n = 7$). Lungs were collected at the end of the experiment, as previously described.¹⁹

Histology and Immunohistochemistry. All mouse tissue samples were fixed in 10% formalin (Sigma) and embedded in paraffin. For spontaneous lung metastasis in MMTV-PyMT animals, the number of metastasis in the lung parenchyma was counted and the size was measured.

Commercial ADME-T Services. hERG inhibition was determined using the "hERG Human Potassium Ion Channel Cell Based Antagonist Qpatch Assay" by Eurofins Ltd. Cell permeability was determined using the "Caco-2 permeability assay" by Cyprotex Ltd.

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.jmedchem.9b00335](https://doi.org/10.1021/acs.jmedchem.9b00335).

Molecular formula strings of all final inhibitors (CSV)

Experimental procedures and characterization data for synthetic intermediates, compounds 11a, 11b, 15, 16, 19, 22c, 22d, 22e, 23c, 23d, 23e, 24c, 24d, 26, 27, 28, 29, 30, 32, 33, 36, 37, 38, 39, 41, 43, 45, 47, 49, 52, 54, 56, 58, 59, and 60 (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: caroline.springer@cruk.manchester.ac.uk.

ORCID

Leo Leung: [0000-0002-6537-6178](https://orcid.org/0000-0002-6537-6178)

Notes

The authors declare the following competing financial interest(s): H.T., L.L., D.N.-D., D.S., C.C., R.Ma. and C.S. have filed a patent application which includes the therapeutic use of aminomethylenethiophene inhibitors such as CCT365623. All authors L.L., D.N.-D., D.S., F.L., C.C., R.Mc., G.S., L.D., M.A., M.B., L.J., A.Z., T.C., D.M., N.B., R.K., L.F., R.L., M.C., H.T., R.Ma. and C.S. could benefit financially if any of the described inhibitors such as CCT365623 is licenced, as part of a reward scheme for employees at ICR and CRUK MI.

■ ACKNOWLEDGMENTS

This work was supported by the CRUK Manchester Institute (C5759/A27412, C5759/A12328), CRUK Manchester Institute Drug Discovery Unit (C480/A17098), the Division of Cancer Therapeutics at The Institute of Cancer Research (C309/A11566, C309/A8274, C107/A10433), and the Wellcome Trust (1003X, 103021/Z/13/Z). We thank Dr. Maggie Liu, Dr. Amin Mirza, and Meirion Richards for assistance with NMR and MS instrumentation. We would also like to thank Dr. Simon Pearce for his advice on statistics.

■ ABBREVIATIONS

AMT, aminomethylenethiophene; BAPN, 3-aminopropionitrile; DAO, diamine oxidase; dba, dibenzylideneacetone; CL, clearance; C_{max} , maximal concentration; DIPEA, *N,N*-diisopropylethylamine; DPPA, diphenyl phosphoryl azide; GEMM, genetically engineered mouse model; HMDS, hexamethyldisilazane; HRP, horseradish peroxidase; LOX, lysyl oxidase; LOXL, lysyl oxidase like; LTQ, lysine tyrosylquinone; MAO, monoamine oxidase; mCPBA, *meta*-chloroperbenzoic acid; MLM, mouse liver microsome; MMTV, mouse mammary tumor virus; PAINS, pan assay interference compounds; PyMT, polyomavirus middle T-antigen; ROS, reactive oxygen species; SSAO, semicarbazide-sensitive amine oxidase

■ REFERENCES

- (1) Finney, J.; Moon, H.-J.; Ronnebaum, T.; Lantz, M.; Mure, M. Human Copper-Dependent Amine Oxidases. *Arch. Biochem. Biophys.* **2014**, *546*, 19–32.
- (2) Kagan, H. M.; Ryvkin, F. Lysyl Oxidase and Lysyl Oxidase-Like Enzymes. In *The Extracellular Matrix: An Overview*, 1st ed.; Mecham, R. P., Ed.; Springer, 2011; pp 303–335.
- (3) Lucero, H. A.; Kagan, H. M. Lysyl Oxidase: an Oxidative Enzyme and Effector of Cell Function. *Cell. Mol. Life Sci.* **2006**, *63*, 2304–2316.
- (4) Kagan, H. M.; Li, W. Lysyl Oxidase: Properties, Specificity, and Biological Roles Inside and Outside of the Cell. *J. Cell. Biochem.* **2003**, *88*, 660–672.
- (5) Wang, T.-H.; Hsia, S.-M.; Shieh, T.-M. Lysyl Oxidase and the Tumor Microenvironment. *Int. J. Mol. Sci.* **2016**, *18*, 62–73.
- (6) Cox, T. R.; Gartland, A.; Erler, J. T. Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis. *Cancer Res.* **2016**, *76*, 188–192.
- (7) Trackman, P. C. Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer. *Expert Opin. Ther. Targets* **2016**, *3*, 935–945.
- (8) Perryman, L.; Erler, J. Lysyl Oxidase in Cancer Research. *Future Oncol.* **2014**, *10*, 1709–1717.
- (9) Barker, H. E.; Cox, T. R.; Erler, J. T. The Rationale for Targeting the LOX Family in Cancer. *Nat. Rev. Cancer* **2012**, *12*, 540–552.
- (10) Nishioka, T.; Eustace, A.; West, C. Lysyl Oxidase: From Basic Science to Future Cancer Treatment. *Cell Struct. Funct.* **2012**, *37*, 75–80.

(11) Siddikuzzaman; Grace, V. M. B.; Guruvayoorappan, C. Lysyl Oxidase: a Potential Target for Cancer Therapy. *Inflammopharmacology* **2011**, *19*, 117–129.

(12) Johnston, K. A.; Lopez, K. M. Lysyl Oxidase in Cancer Inhibition and Metastasis. *Cancer Lett.* **2018**, *417*, 174–181.

(13) Erler, J. T.; Bennewith, K. L.; Nicolau, M.; Dornhofer, N.; Kong, C.; Le, Q. T.; Chi, J. T. A.; Jeffrey, S. S.; Giaccia, A. J. Lysyl Oxidase is Essential for Hypoxia-Induced Metastasis. *Nature* **2006**, *440*, 1222–1226.

(14) Tang, S. S.; Trackman, P. C.; Kagan, H. M. Reaction of Aortic Lysyl Oxidase with beta-Aminopropionitrile. *J. Biol. Chem.* **1983**, *258*, 4331–4338.

(15) Pinnell, S. R.; Martin, G. R. The Cross-Linking of Collagen and Elastin: Enzymatic Conversion of Lysine in Peptide Linage to α -Aminoadipic- δ -Semiaaldehyde (Allysine) by an Extract from Bone. *Proc. Natl. Acad. Sci. U.S.A.* **1968**, *61*, 708–714.

(16) Chang, J.; Lucas, M. C.; Leonte, L. E.; Garcia-Montolio, M.; Singh, L. B.; Findlay, A. D.; Deodhar, M.; Foot, J.; Jarolimek, W.; Timpson, P.; Erler, J. T.; Cox, T. R. Pre-clinical Evaluation of Small Molecule LOXL2 Inhibitors in Breast Cancer. *Oncotarget* **2017**, *8*, 26066–26078.

(17) Rowbottom, M. W.; Bain, G.; Calderon, I.; Lasof, T.; Lonergan, D.; Lai, A.; Huang, F.; Darlington, J.; Prodanovich, P.; Santini, A. M.; King, C. D.; Goulet, L.; Shannon, K. E.; Ma, G. L.; Nguyen, K.; MacKenna, D. A.; Evans, J. F.; Hutchinson, J. H. Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2). *J. Med. Chem.* **2017**, *60*, 4403–4423.

(18) Hutchinson, J. H.; Rowbottom, M. W.; Lonergan, D.; Darlington, J.; Prodanovich, P.; King, C. D.; Evans, J. F.; Bain, G. Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX. *ACS Med. Chem. Lett.* **2017**, *8*, 423–427.

(19) Tang, H. R.; Leung, L.; Saturno, G.; Viros, A.; Smith, D.; Di Leva, G.; Morrison, E.; Niculescu-Duvaz, D.; Lopes, F.; Johnson, L.; Dhomen, N.; Springer, C.; Marais, R. Lysyl Oxidase Drives Tumour Progression by Trapping EGF Receptors at the Cell Surface. *Nat. Commun.* **2017**, *8*, No. 14909.

(20) Rückle, T.; Biamonte, M.; Grippi-Vallotton, T.; Arkininstall, S.; Cambet, Y.; Camps, M.; Chabert, C.; Church, D. J.; Halazy, S.; Jiang, X.; Martinou, I.; Nichols, A.; Sauer, W.; Gotteland, J.-P. Design, Synthesis, and Biological Activity of Novel, Potent, and Selective (Benzoylaminoethyl)thiophene Sulfonamide Inhibitors of c-Jun-N-Terminal Kinase. *J. Med. Chem.* **2004**, *47*, 6921–6934.

(21) Chakraborty, T. K.; Tapadar, S.; Kiran Kumar, S. Cyclic Trimer of 5-(Aminomethyl)-2-furancarboxylic Acid as a Novel Synthetic Receptor for Carboxylate Recognition. *Tetrahedron Lett.* **2002**, *43*, 1317–1320.

(22) Sasaki, T.; Ando, T.; Yamamoto, Y.; Imai, T.; Kubota, D.; Noguchi, K.; Hori, N.; Shitara, E.; Atsumi, K.; Yasuda, S. Intermediate for 2-Substituted Carbapenem Derivative and Production Process. WO2004/055027, 2004.

(23) Baell, J. B.; Holloway, G. A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. *J. Med. Chem.* **2010**, *53*, 2719–2740.

(24) Shackleton, D. R.; Hulmes, D. J. Purification of Lysyl Oxidase from Piglet Skin by Selective Interaction with Sephacryl S-200. *Biochem. J.* **1990**, *266*, 917–919.

(25) Workman, P.; Balmain, A.; Hickman, J. A.; McNally, N. J.; Rohas, A. M.; Mitchison, N. A.; Pierrepont, C. G.; Raymond, R.; Rowlatt, C.; Stephens, T. C.; et al. UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia. *Lab. Anim.* **1988**, *22*, 195–201.